enchanted_elixir
𝕸𝖊𝖗𝖈𝖊𝖓𝖆𝖗𝖞 𝕮𝖔𝖗𝖕 • 𝟐𝟎𝟐𝟐🥉
Contributor
- Joined
- Apr 15, 2022
- Posts
- 24,383
- Reputation
- 43,412
THE COMPLETE NOOTROPICS MASTERCLASS
VOLUME 3: THE LIST OF COMPOUNDS
PART 2 OF 11 | ACTOPROTECTORS, NEUROVASCULAR AGENTS & NEUROTROPHIC COMPOUNDS
VOLUME 3: THE LIST OF COMPOUNDS
PART 2 OF 11 | ACTOPROTECTORS, NEUROVASCULAR AGENTS & NEUROTROPHIC COMPOUNDS
18.11 Actoprotectors and Antihypoxic Metabolic Modulators
An actoprotector is intended to preserve work under harsh physical or metabolic stress without ordinary psychostimulation. Bemitil, Hypoxen, and meldonium have regional histories, but evidence quality, product comparability, and anti-doping consequences require unusually careful labeling.
18.11.1 Bemitil / Bemethyl — Doing More Before Fatigue: A Possible Metabolic Cheat Code
What it is: Bemitil—also spelled bemethyl, bemithyl, or metaprot—is 2-ethylbenzimidazole hydrobromide, a Soviet-developed actoprotector. An actoprotector is intended to increase work capacity under heat, hypoxia, illness, or exhaustive demand without acting like a classic psychostimulant.
What it may feel like: It may be subtle at rest and much clearer under strain. Reports describe being awake and ready to move, breathing and exertion feeling less punishing, and recovering faster after hard work. Others experience restlessness, irritability, headache, nausea, facial warmth, or insomnia. The important image is not forced motivation; it is discovering during the fifth difficult hour that the body and brain are degrading less rapidly than expected.
The simplest description: Bemitil appears to increase production of enzymes and protective proteins that help cells process fuel and withstand stress. It is closer to preparing a factory for a heat wave than borrowing energy from tomorrow with amphetamine.
How It Works
Older Russian literature describes increased transcription and synthesis of enzymes involved in gluconeogenesis, mitochondrial energy production, and antioxidant defense. Bemitil may help recycle lactate and maintain carbohydrate supply during repeated work, while reducing oxidative and heat stress.
This mechanism develops over time. A first capsule may produce little, while repeated exposure across three to five days was reported to build the effect. Mechanistic claims rely heavily on older regional studies and should not be treated as modern target-validation.
Dose and How It Is Taken
Historical medical and performance literature commonly describes 250 mg twice daily after food, often for two-to-five-day courses with breaks. Other weight-based regimens exist. These are historical exposures, not a modern recommendation for a healthy teenager.
Bemitil hydrobromide is orally absorbed and carbohydrate-rich food reportedly accelerates absorption; taking it after a meal also reduces stomach irritation. It crosses the blood–brain barrier. Exact aqueous/lipid solubility, pH behavior, and formulation bioequivalence are not adequately documented in accessible modern sources.
Timing and Pharmacokinetics
The literature includes military, occupational, illness-recovery, heat, altitude, and exercise studies, but much is old, regional, poorly accessible, and below current reporting standards. There is no large modern program demonstrating grades, intelligence, or safe chronic enhancement in healthy adults.
A detailed forum guide reports major changes in resilience, while a stacked experiment with meldonium and Hypoxen described non-jittery wakefulness, easier running, and lingering restlessness. Because the stack contained three agents, it cannot show what bemitil did alone. Single-compound guide, stacked experience
Safety, Interactions, and Monitoring
Possible effects include nausea, abdominal discomfort, headache, facial flushing, activation, irritability, restlessness, and insomnia. Older sources describe liver metabolism, making hepatic disease and multi-drug combinations relevant. Long-term reproductive, cardiovascular, psychiatric, and cancer safety is insufficiently characterized.
Avoid unsupervised use in minors, pregnancy, breastfeeding, serious liver or kidney disease, unstable psychiatric states, and elite sport without checking current anti-doping status. Stop for jaundice, severe agitation, allergic reaction, chest pain, fainting, or persistent insomnia.
There is no modern evidence-based cycling rule, though historical short courses and rest days reflect the tendency for effect and adverse activation to build. Track sleep, blood pressure, heart rate, exercise or work output, recovery, liver markers when appropriate, and product identity. Old brand names do not verify a current tablet.
Tolerance, dependence, withdrawal, and an evidence-based enhancement cycle are not adequately characterized; a multi-day course in regional practice is not proof that cycling prevents risk.
Bottom Line
Bemitil is a historically important actoprotector whose most plausible value appears during genuine stress, not ordinary rest. It may let capacity decay more slowly and recovery occur faster, but modern PK, replication, product quality, and long-term safety remain far thinner than its reputation.
What it is: Bemitil—also spelled bemethyl, bemithyl, or metaprot—is 2-ethylbenzimidazole hydrobromide, a Soviet-developed actoprotector. An actoprotector is intended to increase work capacity under heat, hypoxia, illness, or exhaustive demand without acting like a classic psychostimulant.
What it may feel like: It may be subtle at rest and much clearer under strain. Reports describe being awake and ready to move, breathing and exertion feeling less punishing, and recovering faster after hard work. Others experience restlessness, irritability, headache, nausea, facial warmth, or insomnia. The important image is not forced motivation; it is discovering during the fifth difficult hour that the body and brain are degrading less rapidly than expected.
The simplest description: Bemitil appears to increase production of enzymes and protective proteins that help cells process fuel and withstand stress. It is closer to preparing a factory for a heat wave than borrowing energy from tomorrow with amphetamine.
How It Works
Older Russian literature describes increased transcription and synthesis of enzymes involved in gluconeogenesis, mitochondrial energy production, and antioxidant defense. Bemitil may help recycle lactate and maintain carbohydrate supply during repeated work, while reducing oxidative and heat stress.
This mechanism develops over time. A first capsule may produce little, while repeated exposure across three to five days was reported to build the effect. Mechanistic claims rely heavily on older regional studies and should not be treated as modern target-validation.
Dose and How It Is Taken
Historical medical and performance literature commonly describes 250 mg twice daily after food, often for two-to-five-day courses with breaks. Other weight-based regimens exist. These are historical exposures, not a modern recommendation for a healthy teenager.
Bemitil hydrobromide is orally absorbed and carbohydrate-rich food reportedly accelerates absorption; taking it after a meal also reduces stomach irritation. It crosses the blood–brain barrier. Exact aqueous/lipid solubility, pH behavior, and formulation bioequivalence are not adequately documented in accessible modern sources.
Timing and Pharmacokinetics
- Subjective onset: Roughly one to three hours when an acute effect is noticed.
- Tmax: A dependable modern human value is not publicly established.
- Absorption/bioavailability: Described as fully absorbed in older reviews, but a modern absolute percentage is unavailable.
- Full practical effect: Builds during the first three to five days of a course.
- Half-life and complete elimination: Modern numeric human values are inadequately published; a dosing schedule cannot substitute for measured PK.
- Accumulation/steady state: Functional effect increases over several days, but parent-drug accumulation has not been cleanly separated from induced protein expression.
- Metabolism/elimination: Hepatic biotransformation followed by urinary excretion of drug-related material.
- Subjective duration: When noticed, reports describe several hours of greater stress resistance; the course-level effect can build across days.
- Near-complete elimination: Cannot be calculated from dependable modern human parent-drug PK.
The literature includes military, occupational, illness-recovery, heat, altitude, and exercise studies, but much is old, regional, poorly accessible, and below current reporting standards. There is no large modern program demonstrating grades, intelligence, or safe chronic enhancement in healthy adults.
A detailed forum guide reports major changes in resilience, while a stacked experiment with meldonium and Hypoxen described non-jittery wakefulness, easier running, and lingering restlessness. Because the stack contained three agents, it cannot show what bemitil did alone. Single-compound guide, stacked experience
Safety, Interactions, and Monitoring
Possible effects include nausea, abdominal discomfort, headache, facial flushing, activation, irritability, restlessness, and insomnia. Older sources describe liver metabolism, making hepatic disease and multi-drug combinations relevant. Long-term reproductive, cardiovascular, psychiatric, and cancer safety is insufficiently characterized.
Avoid unsupervised use in minors, pregnancy, breastfeeding, serious liver or kidney disease, unstable psychiatric states, and elite sport without checking current anti-doping status. Stop for jaundice, severe agitation, allergic reaction, chest pain, fainting, or persistent insomnia.
There is no modern evidence-based cycling rule, though historical short courses and rest days reflect the tendency for effect and adverse activation to build. Track sleep, blood pressure, heart rate, exercise or work output, recovery, liver markers when appropriate, and product identity. Old brand names do not verify a current tablet.
Tolerance, dependence, withdrawal, and an evidence-based enhancement cycle are not adequately characterized; a multi-day course in regional practice is not proof that cycling prevents risk.
Bottom Line
Bemitil is a historically important actoprotector whose most plausible value appears during genuine stress, not ordinary rest. It may let capacity decay more slowly and recovery occur faster, but modern PK, replication, product quality, and long-term safety remain far thinner than its reputation.
18.11.2 Hypoxen — Keeping the Lights On When Oxygen Becomes the Bottleneck
What it is: Hypoxen, also called olifen, is sodium polydihydroxyphenylene thiosulfonate—a polyphenolic sulfur-containing polymeric drug sold in parts of Eastern Europe and Central Asia. Because it is a polymeric mixture rather than one small, perfectly uniform molecule, batch and analytical identity are unusually important.
What it may feel like: A clean solo profile does not exist. Stacked anecdotes describe lighter breathing, sustained alertness, and less exhaustion during running; other users report nothing clear. If it works, the relevant feeling would appear under low-oxygen or high-demand conditions as slower fatigue—not as euphoria.
The simplest description: Hypoxen is claimed to help electrons and antioxidant chemistry keep moving when oxygen is scarce. The evidence is too weak to say exactly where or how reliably that happens in humans.
How It Works
Regional descriptions propose that Hypoxen supports mitochondrial respiration, accepts reducing equivalents, reduces oxygen consumption for a given workload, and limits lipid oxidation. Modern independent target and structure–activity work is sparse, so the popular phrase “direct electron shuttle” is more confident than the evidence allows.
The polymeric chemistry also means “mechanism” may represent a mixture of redox-active units rather than one receptor interaction.
Dose and How It Is Taken
Russian product information describes 0.5–1 gram three times daily, before or with food, in short 3–14-day courses. Other weight-based protocols exist. These are regional label exposures—not a nootropic recommendation.
The sodium salt is administered orally with water. Public quantitative data for solubility, pH dependence, absolute bioavailability, BBB penetration, Tmax, plasma half-life, active species, accumulation, and complete elimination are inadequate. A polymer may be transformed in the gut and detected through urinary metabolites without intact systemic absorption.
A 2024 anti-doping analytical study identified urinary markers after oral administration, proving that drug-related material can be detected, but not establishing a clinically useful PK curve. Urinary-metabolite study
Timing and Pharmacokinetics
Older human studies report changes in lactate, oxygen use, recovery, or performance under strenuous conditions. Reporting quality and independent replication are limited. Hypoxen entered WADA’s Monitoring Program, which means use is being observed; monitoring is not the same as a formal prohibited status or proof of efficacy.
The clearest online experience combines Hypoxen with bemitil and meldonium, producing wakefulness and an easier run. It cannot isolate Hypoxen, and the author was recovering from a respiratory infection. Stacked anecdote
Safety, Interactions, and Monitoring
Regional labeling lists individual intolerance and avoids use in pregnancy, breastfeeding, and hemorrhagic stroke. Modern incidence, drug interactions, organ toxicity, reproductive safety, and chronic redox effects are not adequately characterized.
Avoid unsupervised use in minors, bleeding or cerebrovascular disease, serious liver or kidney disease, and competition without current anti-doping review. Stop for allergic symptoms, severe headache, neurological change, persistent gastrointestinal illness, chest pain, or fainting.
No evidence-based cycle or washout exists beyond regional short courses. Product testing must address polymer identity, sulfur content, sodium, molecular distribution, and contaminants—not merely a single purity percentage.
Bottom Line
Hypoxen has a plausible antihypoxic purpose and a remarkably incomplete modern evidence package. It should be presented as a poorly characterized regional polymer with uncertain PK, not as a precise mitochondrial electron shuttle with a dependable performance effect.
What it is: Hypoxen, also called olifen, is sodium polydihydroxyphenylene thiosulfonate—a polyphenolic sulfur-containing polymeric drug sold in parts of Eastern Europe and Central Asia. Because it is a polymeric mixture rather than one small, perfectly uniform molecule, batch and analytical identity are unusually important.
What it may feel like: A clean solo profile does not exist. Stacked anecdotes describe lighter breathing, sustained alertness, and less exhaustion during running; other users report nothing clear. If it works, the relevant feeling would appear under low-oxygen or high-demand conditions as slower fatigue—not as euphoria.
The simplest description: Hypoxen is claimed to help electrons and antioxidant chemistry keep moving when oxygen is scarce. The evidence is too weak to say exactly where or how reliably that happens in humans.
How It Works
Regional descriptions propose that Hypoxen supports mitochondrial respiration, accepts reducing equivalents, reduces oxygen consumption for a given workload, and limits lipid oxidation. Modern independent target and structure–activity work is sparse, so the popular phrase “direct electron shuttle” is more confident than the evidence allows.
The polymeric chemistry also means “mechanism” may represent a mixture of redox-active units rather than one receptor interaction.
Dose and How It Is Taken
Russian product information describes 0.5–1 gram three times daily, before or with food, in short 3–14-day courses. Other weight-based protocols exist. These are regional label exposures—not a nootropic recommendation.
The sodium salt is administered orally with water. Public quantitative data for solubility, pH dependence, absolute bioavailability, BBB penetration, Tmax, plasma half-life, active species, accumulation, and complete elimination are inadequate. A polymer may be transformed in the gut and detected through urinary metabolites without intact systemic absorption.
A 2024 anti-doping analytical study identified urinary markers after oral administration, proving that drug-related material can be detected, but not establishing a clinically useful PK curve. Urinary-metabolite study
Timing and Pharmacokinetics
- Subjective onset: Anecdotally within hours.
- Full practical effect: Regional protocols imply same-day and course effects, but no validated human clock exists.
- Near-complete elimination: Unknown; anti-doping detection windows must follow current laboratory guidance.
- Absorption/bioavailability: Oral use exists regionally, but absolute exposure for this polymeric mixture is not adequately characterized.
- Subjective duration: Unknown; stacked anecdotes suggest same-day effects under exertion but do not define a reproducible window.
- Half-life: No defensible modern human mixture-wide value is available.
- Accumulation/steady state: Unknown; a polymeric mixture cannot be assigned one accumulation ratio without constituent-specific assays.
- Metabolism/elimination: Human breakdown products and renal or biliary excretion fractions are not adequately mapped.
Older human studies report changes in lactate, oxygen use, recovery, or performance under strenuous conditions. Reporting quality and independent replication are limited. Hypoxen entered WADA’s Monitoring Program, which means use is being observed; monitoring is not the same as a formal prohibited status or proof of efficacy.
The clearest online experience combines Hypoxen with bemitil and meldonium, producing wakefulness and an easier run. It cannot isolate Hypoxen, and the author was recovering from a respiratory infection. Stacked anecdote
Safety, Interactions, and Monitoring
Regional labeling lists individual intolerance and avoids use in pregnancy, breastfeeding, and hemorrhagic stroke. Modern incidence, drug interactions, organ toxicity, reproductive safety, and chronic redox effects are not adequately characterized.
Avoid unsupervised use in minors, bleeding or cerebrovascular disease, serious liver or kidney disease, and competition without current anti-doping review. Stop for allergic symptoms, severe headache, neurological change, persistent gastrointestinal illness, chest pain, or fainting.
No evidence-based cycle or washout exists beyond regional short courses. Product testing must address polymer identity, sulfur content, sodium, molecular distribution, and contaminants—not merely a single purity percentage.
Bottom Line
Hypoxen has a plausible antihypoxic purpose and a remarkably incomplete modern evidence package. It should be presented as a poorly characterized regional polymer with uncertain PK, not as a precise mitochondrial electron shuttle with a dependable performance effect.
18.11.3 Meldonium — Spending Less Oxygen for the Same ATP
What it is: Meldonium, or mildronate, is a water-soluble structural analog of gamma-butyrobetaine used medically in several countries for ischemic cardiovascular conditions. It reduces carnitine synthesis and transport, changing which fuels mitochondria prefer.
What it may feel like: Usually not much while sitting still. Under prolonged mental or physical demand, the difference may become obvious only in retrospect: six hours into difficult work, the usual energetic collapse is smaller, and after exhaustion the person may feel able to regenerate and begin another block sooner. During endurance work, breathing and effort may feel smoother. Other people feel nothing or develop headache, agitation, palpitations, gastrointestinal discomfort, or poor sleep.
The simplest description: Fat yields abundant energy but costs more oxygen per ATP than glucose. Meldonium shifts part of metabolism away from fatty-acid oxidation toward glucose so the body can extract more usable work from limited oxygen.
How It Works
Meldonium inhibits gamma-butyrobetaine hydroxylase and reduces carnitine-dependent entry of long-chain fatty acids into mitochondria. This limits incomplete fatty-acid oxidation and favors glucose oxidation, particularly under ischemia or hypoxia. Gamma-butyrobetaine accumulation may also support nitric-oxide-related vascular effects.
This is not unlimited energy. It changes fuel economics. The benefit should be most visible when oxygen delivery or metabolic demand is actually constraining performance; a healthy person doing an easy task may notice nothing.
Dose and How It Is Taken
Medical and clinical studies commonly use 500–1,000 mg/day orally, often divided, while disease trials have examined lower and much higher amounts. A common athlete PK study used 500 mg twice daily. These are studied exposures and prescription regimens, not instructions for healthy enhancement.
Meldonium is highly water-soluble and does not require dietary fat. Oral bioavailability is about 78%. It may be taken with or without food; food delays the peak without greatly changing peak concentration. Morning and early-afternoon use is more practical if it feels activating.
Timing and Pharmacokinetics
Evidence is strongest in angina, heart failure, ischemia, and reduced exercise tolerance—not healthy cognition. Some trials report improved exercise duration in cardiovascular patients. Direct evidence that meldonium enables healthy students to think longer is absent; the cognitively sustained-energy description is a mechanistic and anecdotal extrapolation that needs testing.
Online users describe smooth endurance, lower perceived breathing cost, alertness without a stimulant crash, and restlessness. Because meldonium is frequently stacked with bemitil or Hypoxen, attribution is poor. Stacked experience
Meldonium has been prohibited by WADA since 2016. Competitive athletes must not treat a prescription in one country or a long washout guess as anti-doping clearance.
Safety, Interactions, and Monitoring
Possible adverse effects include headache, dyspepsia, nausea, allergic reaction, agitation, sleep disturbance, blood-pressure change, and tachycardia or palpitations. It may add to antianginal, blood-pressure-lowering, or vasodilator medication. Renal elimination makes kidney function particularly relevant.
Avoid unsupervised use in minors, pregnancy, breastfeeding, serious kidney or liver disease, unstable cardiovascular illness, increased intracranial pressure, and drug-tested sport. Stop for chest pain, fainting, severe palpitations, allergic swelling, neurological deterioration, or jaundice.
Classic dependence is not expected, but metabolic adaptation and very long terminal elimination make casual cycling poorly defined. Track resting heart rate, blood pressure, sleep, exercise or cognitive endurance, recovery time, kidney and liver measures when appropriate, and competition status.
Product quality matters because hydrate form, assay, dose uniformity, and contaminants determine exposure; use of a regulated regional medicine cannot validate an anonymous sports-performance powder.
Bottom Line
Meldonium is an oxygen-economy drug. Its most vivid plausible benefit is not feeling stimulated; it is reaching the point where competitors or classmates are metabolically exhausted and realizing that you still have usable capacity—or can recover for the next block faster. That application remains much better supported in cardiovascular and physical settings than in healthy cognition.
What it is: Meldonium, or mildronate, is a water-soluble structural analog of gamma-butyrobetaine used medically in several countries for ischemic cardiovascular conditions. It reduces carnitine synthesis and transport, changing which fuels mitochondria prefer.
What it may feel like: Usually not much while sitting still. Under prolonged mental or physical demand, the difference may become obvious only in retrospect: six hours into difficult work, the usual energetic collapse is smaller, and after exhaustion the person may feel able to regenerate and begin another block sooner. During endurance work, breathing and effort may feel smoother. Other people feel nothing or develop headache, agitation, palpitations, gastrointestinal discomfort, or poor sleep.
The simplest description: Fat yields abundant energy but costs more oxygen per ATP than glucose. Meldonium shifts part of metabolism away from fatty-acid oxidation toward glucose so the body can extract more usable work from limited oxygen.
How It Works
Meldonium inhibits gamma-butyrobetaine hydroxylase and reduces carnitine-dependent entry of long-chain fatty acids into mitochondria. This limits incomplete fatty-acid oxidation and favors glucose oxidation, particularly under ischemia or hypoxia. Gamma-butyrobetaine accumulation may also support nitric-oxide-related vascular effects.
This is not unlimited energy. It changes fuel economics. The benefit should be most visible when oxygen delivery or metabolic demand is actually constraining performance; a healthy person doing an easy task may notice nothing.
Dose and How It Is Taken
Medical and clinical studies commonly use 500–1,000 mg/day orally, often divided, while disease trials have examined lower and much higher amounts. A common athlete PK study used 500 mg twice daily. These are studied exposures and prescription regimens, not instructions for healthy enhancement.
Meldonium is highly water-soluble and does not require dietary fat. Oral bioavailability is about 78%. It may be taken with or without food; food delays the peak without greatly changing peak concentration. Morning and early-afternoon use is more practical if it feels activating.
Timing and Pharmacokinetics
- Subjective onset: Approximately one to three hours when noticeable, but endurance effects may become clear only after sustained work.
- Tmax: Roughly 1–2 hours.
- Initial half-life: Commonly 3–7 hours after a single dose, with reviews reporting 5–15 hours depending on regimen.
- Long terminal phase: Repeated dosing can produce a terminal half-life exceeding 100 hours in some analyses.
- Accumulation/full effect: Carnitine-system changes build over days to weeks; clinical performance studies often use several weeks.
- Near-complete elimination: Plasma can fall quickly while tissue and urinary residues persist for weeks or months after repeated exposure. A one-day washout is false.
- Metabolism/elimination: Limited metabolism plus predominantly renal elimination; exposure rises with serious kidney or liver dysfunction.
- Absorption/bioavailability: Oral absorption is substantial, but estimates vary by formulation and study; regulated regional products—not loose powder—anchor the published exposure.
- Full practical effect: Acute sensations can appear the same day, while carnitine-system and performance effects build over days to weeks.
- Subjective duration: A single dose may feel active for hours, but metabolic and tissue effects can persist far beyond the obvious sensation.
- Half-life: The early plasma phase is commonly 3–7 hours, while repeated dosing can reveal a terminal phase exceeding 100 hours.
- Accumulation/steady state: Repeated use accumulates in tissues and changes the carnitine system; a simple one-day steady-state assumption is false.
Evidence is strongest in angina, heart failure, ischemia, and reduced exercise tolerance—not healthy cognition. Some trials report improved exercise duration in cardiovascular patients. Direct evidence that meldonium enables healthy students to think longer is absent; the cognitively sustained-energy description is a mechanistic and anecdotal extrapolation that needs testing.
Online users describe smooth endurance, lower perceived breathing cost, alertness without a stimulant crash, and restlessness. Because meldonium is frequently stacked with bemitil or Hypoxen, attribution is poor. Stacked experience
Meldonium has been prohibited by WADA since 2016. Competitive athletes must not treat a prescription in one country or a long washout guess as anti-doping clearance.
Safety, Interactions, and Monitoring
Possible adverse effects include headache, dyspepsia, nausea, allergic reaction, agitation, sleep disturbance, blood-pressure change, and tachycardia or palpitations. It may add to antianginal, blood-pressure-lowering, or vasodilator medication. Renal elimination makes kidney function particularly relevant.
Avoid unsupervised use in minors, pregnancy, breastfeeding, serious kidney or liver disease, unstable cardiovascular illness, increased intracranial pressure, and drug-tested sport. Stop for chest pain, fainting, severe palpitations, allergic swelling, neurological deterioration, or jaundice.
Classic dependence is not expected, but metabolic adaptation and very long terminal elimination make casual cycling poorly defined. Track resting heart rate, blood pressure, sleep, exercise or cognitive endurance, recovery time, kidney and liver measures when appropriate, and competition status.
Product quality matters because hydrate form, assay, dose uniformity, and contaminants determine exposure; use of a regulated regional medicine cannot validate an anonymous sports-performance powder.
Bottom Line
Meldonium is an oxygen-economy drug. Its most vivid plausible benefit is not feeling stimulated; it is reaching the point where competitors or classmates are metabolically exhausted and realizing that you still have usable capacity—or can recover for the next block faster. That application remains much better supported in cardiovascular and physical settings than in healthy cognition.
18.12 Metabolic–Neurotrophic Bridge Compounds
J147 is placed here because its preclinical story connects ATP-synthase-related metabolism to synaptic and neurotrophic outcomes. That bridge is a research program, not proof of human benefit.
18.12.1 J147 — A Neurotrophic Metabolic Drug That Has Not Yet Earned a Human Dose
What it is: J147 is a synthetic, brain-penetrant small molecule created through phenotypic screening for neuroprotection and cognition. It is often called a curcumin derivative, but its pharmacology and chemical identity are distinct from curcumin.
What it may feel like: No controlled human profile is available. One detailed self-experimenter described J147 alone as mild and initially sleep-inducing, with more noticeable sensory or cognitive effects when stacked; other reports are too sparse to identify a pattern. A claimed profound effect from an unverified research chemical is not a substitute for a Phase I result.
The simplest description: J147 appears to mildly stress and retune mitochondrial energy machinery in a way that activates protective, growth-related responses. It tries to make an old or damaged brain behave as though its repair systems were younger; this remains a mouse result.
How It Works
J147 binds the alpha subunit of mitochondrial ATP synthase in preclinical work, changing mitochondrial signaling and activating AMPK-related, neurotrophic, inflammatory, and synaptic pathways. Animal studies report increased BDNF-related signaling, improved memory, and reversal of selected aging or Alzheimer-like phenotypes.
The mechanism is hormetic rather than “more ATP synthase equals more energy.” A small perturbation may induce protective adaptation; the wrong exposure could instead impair energy production. Mouse cognitive rescue does not establish safe enhancement in a young human.
Dose and How It Is Taken
There is no published validated human dose. A single-ascending-dose Phase I trial in healthy adults was registered, but publicly accessible peer-reviewed results and a usable human PK table have not been found. Registered Phase I study
J147 is lipophilic and poorly water-soluble, with oral and brain exposure demonstrated in mice. Gray-market oral powders cannot inherit animal formulation or exposure.
J147 has unusually broad and impressive mouse data across cognition, synaptic proteins, inflammation, metabolism, and Alzheimer-like pathology. Those are preclinical disease models, not clinical replication.
The main Reddit report calls J147 mild alone, sometimes nap-inducing, and more apparent with stimulating compounds. The mixture and uncertain product identity prevent attribution. Representative experience
Safety, Interactions, and Monitoring
Human adverse-effect incidence, target exposure, cardiac and liver safety, reproductive effects, cancer implications, and drug interactions remain unpublished. Mitochondrial ATP-synthase modulation creates particular reason not to infer safety from a lack of acute sensation.
Avoid human use outside authorized research, especially in minors, pregnancy, breastfeeding, active cancer, mitochondrial disease, and complex neurological medication. Stop for profound weakness, persistent vomiting, jaundice, chest pain, fainting, neurological change, or severe mood disturbance.
A legitimate study needs authenticated material, ECG, vitals, liver and kidney labs, metabolomics, cognitive testing, sleep, mood, and long follow-up. A vendor assay reporting “99% purity” cannot supply toxicology or human PK.
Human tolerance, withdrawal, dependence, cycling, and interaction washout are unknown.
Bottom Line
J147 is one of the more scientifically interesting neurotrophic-metabolic research drugs in the guide and one of the easiest to overstate. Until human PK and safety results exist, neither a dose nor a dependable feeling can honestly be supplied.
What it is: J147 is a synthetic, brain-penetrant small molecule created through phenotypic screening for neuroprotection and cognition. It is often called a curcumin derivative, but its pharmacology and chemical identity are distinct from curcumin.
What it may feel like: No controlled human profile is available. One detailed self-experimenter described J147 alone as mild and initially sleep-inducing, with more noticeable sensory or cognitive effects when stacked; other reports are too sparse to identify a pattern. A claimed profound effect from an unverified research chemical is not a substitute for a Phase I result.
The simplest description: J147 appears to mildly stress and retune mitochondrial energy machinery in a way that activates protective, growth-related responses. It tries to make an old or damaged brain behave as though its repair systems were younger; this remains a mouse result.
How It Works
J147 binds the alpha subunit of mitochondrial ATP synthase in preclinical work, changing mitochondrial signaling and activating AMPK-related, neurotrophic, inflammatory, and synaptic pathways. Animal studies report increased BDNF-related signaling, improved memory, and reversal of selected aging or Alzheimer-like phenotypes.
The mechanism is hormetic rather than “more ATP synthase equals more energy.” A small perturbation may induce protective adaptation; the wrong exposure could instead impair energy production. Mouse cognitive rescue does not establish safe enhancement in a young human.
Dose and How It Is Taken
There is no published validated human dose. A single-ascending-dose Phase I trial in healthy adults was registered, but publicly accessible peer-reviewed results and a usable human PK table have not been found. Registered Phase I study
J147 is lipophilic and poorly water-soluble, with oral and brain exposure demonstrated in mice. Gray-market oral powders cannot inherit animal formulation or exposure.
- Human absorption and absolute bioavailability: Unknown.
- Human subjective onset, Tmax, half-life, duration, accumulation, full effect, and complete elimination: Unknown.
- Food effect and best timing: Unknown.
- BBB penetration: Demonstrated in animals, not quantified in published human PK.
- Cycling and washout: No evidence-based protocol exists.
- Subjective onset: Unknown; sparse reports range from the first day to gradual change or no response.
- Absorption/bioavailability: Human oral dosing has occurred, but absolute bioavailability is not adequately public.
- Full practical effect: Unknown; repeated animal exposure cannot establish a human timetable.
- Subjective duration: Unknown; isolated reports of sedation or clarity do not define PK.
- Half-life: No dependable public human value is available.
- Accumulation/steady state: Unknown in humans.
- Near-complete elimination: Cannot be calculated without validated human PK.
- Metabolism/elimination: Public human metabolic and mass-balance data are inadequate.
J147 has unusually broad and impressive mouse data across cognition, synaptic proteins, inflammation, metabolism, and Alzheimer-like pathology. Those are preclinical disease models, not clinical replication.
The main Reddit report calls J147 mild alone, sometimes nap-inducing, and more apparent with stimulating compounds. The mixture and uncertain product identity prevent attribution. Representative experience
Safety, Interactions, and Monitoring
Human adverse-effect incidence, target exposure, cardiac and liver safety, reproductive effects, cancer implications, and drug interactions remain unpublished. Mitochondrial ATP-synthase modulation creates particular reason not to infer safety from a lack of acute sensation.
Avoid human use outside authorized research, especially in minors, pregnancy, breastfeeding, active cancer, mitochondrial disease, and complex neurological medication. Stop for profound weakness, persistent vomiting, jaundice, chest pain, fainting, neurological change, or severe mood disturbance.
A legitimate study needs authenticated material, ECG, vitals, liver and kidney labs, metabolomics, cognitive testing, sleep, mood, and long follow-up. A vendor assay reporting “99% purity” cannot supply toxicology or human PK.
Human tolerance, withdrawal, dependence, cycling, and interaction washout are unknown.
Bottom Line
J147 is one of the more scientifically interesting neurotrophic-metabolic research drugs in the guide and one of the easiest to overstate. Until human PK and safety results exist, neither a dose nor a dependable feeling can honestly be supplied.
18.13 Neurovascular Delivery
Even perfect mitochondrial machinery fails without blood delivering oxygen and substrate. Vascular drugs can alter this delivery system, but a healthy brain autoregulates flow; lowering blood pressure or causing headache is not the same as feeding cognition.
18.13.1 Vinpocetine — Cerebral Blood-Flow Modulation With a Short Clock
What it is: Vinpocetine is a synthetic derivative of vincamine, an alkaloid from periwinkle. It is used as a medicine in some countries, while the FDA has questioned whether it legally qualifies as a dietary supplement in the United States and warns women who could become pregnant.
What it may feel like: Responders describe a clearer, less congested head, easier word retrieval, less brain fog, or slightly brighter sensory processing within an hour or two. Others feel nothing or develop headache, dizziness, flushing, nausea, low blood pressure, or a paradoxically foggy state. It should not feel like amphetamine; it changes delivery and signaling more than reward.
The simplest description: Vinpocetine opens parts of the brain’s microvascular plumbing and changes how neurons handle electrical and inflammatory stress. Better plumbing helps when delivery was poor; excessive vasodilation can simply produce a headache.
How It Works
Vinpocetine inhibits PDE1, increasing cyclic-nucleotide signaling in vascular smooth muscle, and interacts with voltage-gated sodium channels and inflammatory pathways. Human imaging and physiological work supports effects on cerebral blood flow and oxygen/glucose handling, although “selectively increases blood only where needed” is stronger than the evidence.
Central and peripheral effects coexist. A clearer head does not prove that memory formation improved, and lower blood pressure can reduce brain perfusion in a susceptible person.
Dose and How It Is Taken
Clinical and regional regimens commonly use 5–10 mg three times daily, while supplement users often take 5–20 mg at once. These are studied or marketed exposures, not a universal recommendation.
Vinpocetine is poorly water-soluble and lipophilic. Taking an oral tablet with food generally improves exposure and stomach tolerance; it is not an empty-stomach compound merely because a faster hit sounds desirable.
Timing and Pharmacokinetics
Vinpocetine has clinical literature in cerebrovascular disease, stroke recovery, cognitive impairment, tinnitus, and dementia, but study quality is variable and several older trials do not meet modern standards. Evidence for a meaningful cognitive improvement in healthy young adults is inadequate.
Online reports include rapid clearing of long-COVID or insomnia-related brain fog, but many involve stacks. One user combined vinpocetine with lecithin, tyrosine, tongkat, and DMAE, so the vivid “unfogging” cannot be assigned to vinpocetine alone. Stacked experience, brain-fog report
Safety, Interactions, and Monitoring
Possible effects include headache, dizziness, flushing, nausea, dry mouth, sleep change, tachycardia or palpitations, and reduced blood pressure. Caution is warranted with antihypertensives, PDE inhibitors, antiplatelet or anticoagulant drugs, and rhythm disorders.
The FDA advises pregnant women and women who could become pregnant not to take vinpocetine because animal data suggest miscarriage or fetal-development risk. FDA warning
Stop for fainting, severe palpitations, abnormal bleeding, sudden neurological symptoms, severe headache, vision change, or allergic reaction. No classic dependence is expected, and cycling is unnecessary. Track blood pressure, pulse, headache, sleep, brain-fog severity, and a repeatable cognitive test. Verify tablet dose; U.S. supplement labeling has been inconsistent.
Bottom Line
Vinpocetine is a short-acting neurovascular drug that may make impaired cerebral delivery feel clearer within hours. Its healthy-cognition evidence is weak, its blood-pressure and pregnancy risks are real, and “more blood flow” is not synonymous with more intelligence.
What it is: Vinpocetine is a synthetic derivative of vincamine, an alkaloid from periwinkle. It is used as a medicine in some countries, while the FDA has questioned whether it legally qualifies as a dietary supplement in the United States and warns women who could become pregnant.
What it may feel like: Responders describe a clearer, less congested head, easier word retrieval, less brain fog, or slightly brighter sensory processing within an hour or two. Others feel nothing or develop headache, dizziness, flushing, nausea, low blood pressure, or a paradoxically foggy state. It should not feel like amphetamine; it changes delivery and signaling more than reward.
The simplest description: Vinpocetine opens parts of the brain’s microvascular plumbing and changes how neurons handle electrical and inflammatory stress. Better plumbing helps when delivery was poor; excessive vasodilation can simply produce a headache.
How It Works
Vinpocetine inhibits PDE1, increasing cyclic-nucleotide signaling in vascular smooth muscle, and interacts with voltage-gated sodium channels and inflammatory pathways. Human imaging and physiological work supports effects on cerebral blood flow and oxygen/glucose handling, although “selectively increases blood only where needed” is stronger than the evidence.
Central and peripheral effects coexist. A clearer head does not prove that memory formation improved, and lower blood pressure can reduce brain perfusion in a susceptible person.
Dose and How It Is Taken
Clinical and regional regimens commonly use 5–10 mg three times daily, while supplement users often take 5–20 mg at once. These are studied or marketed exposures, not a universal recommendation.
Vinpocetine is poorly water-soluble and lipophilic. Taking an oral tablet with food generally improves exposure and stomach tolerance; it is not an empty-stomach compound merely because a faster hit sounds desirable.
Timing and Pharmacokinetics
- Subjective onset: Approximately 30–120 minutes.
- Tmax: Roughly 1.5–2 hours.
- Parent half-life: Commonly 1–2.5 hours, with some product information reporting a longer biological estimate near 4.8 hours.
- Subjective duration: Often 3–6 hours subjectively.
- Accumulation/steady state: Limited for parent vinpocetine with ordinary divided use; the major metabolite has its own kinetics.
- Near-complete elimination: Most parent drug clears within roughly one day.
- Metabolism/elimination: Extensive first-pass hydrolysis in the liver to apovincaminic acid and other metabolites.
- Absorption/bioavailability: Formulation- and food-dependent and often described around 50–60%, but study estimates vary.
- BBB: Central effects and brain imaging support CNS exposure.
- Full practical effect: Acute vascular or cognitive sensations usually peak within the first few hours; clinical cognitive outcomes are assessed over repeated use.
- Half-life: Parent-drug estimates are commonly 1–2.5 hours, while some product information reports a longer biological estimate near 4.8 hours.
Vinpocetine has clinical literature in cerebrovascular disease, stroke recovery, cognitive impairment, tinnitus, and dementia, but study quality is variable and several older trials do not meet modern standards. Evidence for a meaningful cognitive improvement in healthy young adults is inadequate.
Online reports include rapid clearing of long-COVID or insomnia-related brain fog, but many involve stacks. One user combined vinpocetine with lecithin, tyrosine, tongkat, and DMAE, so the vivid “unfogging” cannot be assigned to vinpocetine alone. Stacked experience, brain-fog report
Safety, Interactions, and Monitoring
Possible effects include headache, dizziness, flushing, nausea, dry mouth, sleep change, tachycardia or palpitations, and reduced blood pressure. Caution is warranted with antihypertensives, PDE inhibitors, antiplatelet or anticoagulant drugs, and rhythm disorders.
The FDA advises pregnant women and women who could become pregnant not to take vinpocetine because animal data suggest miscarriage or fetal-development risk. FDA warning
Stop for fainting, severe palpitations, abnormal bleeding, sudden neurological symptoms, severe headache, vision change, or allergic reaction. No classic dependence is expected, and cycling is unnecessary. Track blood pressure, pulse, headache, sleep, brain-fog severity, and a repeatable cognitive test. Verify tablet dose; U.S. supplement labeling has been inconsistent.
Bottom Line
Vinpocetine is a short-acting neurovascular drug that may make impaired cerebral delivery feel clearer within hours. Its healthy-cognition evidence is weak, its blood-pressure and pregnancy risks are real, and “more blood flow” is not synonymous with more intelligence.
18.13.2 Low-Dose Tadalafil (Cialis) — Long-Acting Vascular Support, Not a Brain-Only Drug
What it is: Tadalafil is a prescription PDE5 inhibitor approved for erectile dysfunction, benign prostatic hyperplasia, and—under different branding/dosing—pulmonary arterial hypertension. Low-dose daily tablets are typically 2.5 or 5 mg.
What it may feel like: Some users with vascular dysfunction describe being more grounded, mentally present, physically warm, or free of brain fog. Others feel only the expected erectile effect, and some develop a long headache, nasal congestion, reflux, back pain, dizziness, pounding heartbeat, or worse brain fog. Because tadalafil lasts for days, a bad first response can also last much longer than expected.
The simplest description: Tadalafil stops PDE5 from draining the nitric-oxide/cGMP vasodilation signal. It keeps blood vessels more willing to relax; it does not tell blood to flow only to the brain.
How It Works
Nitric oxide raises cGMP in smooth muscle, and PDE5 breaks cGMP down. Tadalafil inhibits PDE5, prolonging vascular relaxation in responsive tissue. It has some CNS penetration, but most obvious effects are peripheral—penile, pulmonary, urinary, vascular, and muscular.
If cerebral perfusion is impaired, better vascular responsiveness may improve clarity. If baseline blood pressure is low or vessels dilate too much, the same action can produce headache, dizziness, and worse cognition.
Dose and How It Is Taken
Approved daily doses: 2.5–5 mg once daily for ED/BPH contexts. As-needed ED doses: 10–20 mg. The daily dose is the relevant “low-dose” exposure; higher as-needed dosing is not a stronger nootropic protocol.
Tadalafil is poorly water-soluble but formulated for reliable oral absorption. Food does not meaningfully change its rate or extent of absorption, so it can be taken with or without meals. Grapefruit and strong CYP3A4 inhibitors can increase exposure.
Timing and Pharmacokinetics
Small clinical studies in men with erectile dysfunction and mild cognitive impairment report changes in cerebral perfusion and selected cognition after daily low-dose use. The population already had vascular and cognitive impairment, and uncontrolled or small studies do not establish healthy-student enhancement. MCI/ED study
Reddit reports vividly include both major relief of brain fog at 2.5–5 mg and headache or worse fog even at 2.5 mg. This variability is what vascular pharmacology predicts. Positive report, adverse report
Safety, Interactions, and Monitoring
Never combine tadalafil with nitrates such as nitroglycerin or isosorbide, or with riociguat; dangerous hypotension can result. Alpha blockers, multiple antihypertensives, heavy alcohol, and other PDE5 inhibitors also require caution. Strong CYP3A4 inhibitors increase exposure, while inducers reduce it.
Common effects include headache, flushing, nasal congestion, dyspepsia, reflux, back or muscle pain, and dizziness. Seek urgent care for an erection lasting more than four hours, sudden vision or hearing loss, chest pain, fainting, or severe allergic reaction. People with unstable cardiovascular disease, recent stroke/heart attack, severe hypotension, retinal-risk conditions, or serious renal/hepatic impairment need medical evaluation.
Dependence is not expected, and cycling is unnecessary. Track blood pressure, headaches, reflux, vision/hearing, erection duration, sleep, and the cognitive outcome. Use a prescribed pharmacy product; counterfeit ED medication is a major sourcing risk.
Tolerance to the erectile response is not usually the central problem, but headache, congestion, blood-pressure effects, interaction risk, and psychological reliance can make continued escalation irrational; no nootropic cycling rule exists.
Bottom Line
Low-dose tadalafil can plausibly improve clarity when vascular dysfunction is part of the bottleneck, and it can just as plausibly create a 24-hour headache when it is not. Its long half-life, prescription interactions, and systemic effects make it a vascular drug with possible cognitive consequences—not a casual blood-flow supplement.
What it is: Tadalafil is a prescription PDE5 inhibitor approved for erectile dysfunction, benign prostatic hyperplasia, and—under different branding/dosing—pulmonary arterial hypertension. Low-dose daily tablets are typically 2.5 or 5 mg.
What it may feel like: Some users with vascular dysfunction describe being more grounded, mentally present, physically warm, or free of brain fog. Others feel only the expected erectile effect, and some develop a long headache, nasal congestion, reflux, back pain, dizziness, pounding heartbeat, or worse brain fog. Because tadalafil lasts for days, a bad first response can also last much longer than expected.
The simplest description: Tadalafil stops PDE5 from draining the nitric-oxide/cGMP vasodilation signal. It keeps blood vessels more willing to relax; it does not tell blood to flow only to the brain.
How It Works
Nitric oxide raises cGMP in smooth muscle, and PDE5 breaks cGMP down. Tadalafil inhibits PDE5, prolonging vascular relaxation in responsive tissue. It has some CNS penetration, but most obvious effects are peripheral—penile, pulmonary, urinary, vascular, and muscular.
If cerebral perfusion is impaired, better vascular responsiveness may improve clarity. If baseline blood pressure is low or vessels dilate too much, the same action can produce headache, dizziness, and worse cognition.
Dose and How It Is Taken
Approved daily doses: 2.5–5 mg once daily for ED/BPH contexts. As-needed ED doses: 10–20 mg. The daily dose is the relevant “low-dose” exposure; higher as-needed dosing is not a stronger nootropic protocol.
Tadalafil is poorly water-soluble but formulated for reliable oral absorption. Food does not meaningfully change its rate or extent of absorption, so it can be taken with or without meals. Grapefruit and strong CYP3A4 inhibitors can increase exposure.
Timing and Pharmacokinetics
- Subjective onset: Often 30–120 minutes.
- Tmax: Median approximately 2 hours, with a broad range.
- Absorption/bioavailability: Not publicly assigned as a simple percentage in the label.
- Half-life: Approximately 17.5 hours.
- Subjective duration: Erectile/vascular responsiveness can remain altered for up to 36 hours after an as-needed dose.
- Accumulation/steady state: Approximately five days of daily dosing, with about 1.6-fold accumulation.
- Near-complete elimination: Roughly four days for more than 95% of parent exposure after a single dose, longer with accumulation or organ impairment.
- Metabolism/elimination: Primarily CYP3A4 to inactive catechol-related metabolites.
- Excretion: Mostly fecal metabolites, with a smaller urinary fraction.
- Full practical effect: Vascular responsiveness develops over the first several hours; daily exposure stabilizes after about five days.
Small clinical studies in men with erectile dysfunction and mild cognitive impairment report changes in cerebral perfusion and selected cognition after daily low-dose use. The population already had vascular and cognitive impairment, and uncontrolled or small studies do not establish healthy-student enhancement. MCI/ED study
Reddit reports vividly include both major relief of brain fog at 2.5–5 mg and headache or worse fog even at 2.5 mg. This variability is what vascular pharmacology predicts. Positive report, adverse report
Safety, Interactions, and Monitoring
Never combine tadalafil with nitrates such as nitroglycerin or isosorbide, or with riociguat; dangerous hypotension can result. Alpha blockers, multiple antihypertensives, heavy alcohol, and other PDE5 inhibitors also require caution. Strong CYP3A4 inhibitors increase exposure, while inducers reduce it.
Common effects include headache, flushing, nasal congestion, dyspepsia, reflux, back or muscle pain, and dizziness. Seek urgent care for an erection lasting more than four hours, sudden vision or hearing loss, chest pain, fainting, or severe allergic reaction. People with unstable cardiovascular disease, recent stroke/heart attack, severe hypotension, retinal-risk conditions, or serious renal/hepatic impairment need medical evaluation.
Dependence is not expected, and cycling is unnecessary. Track blood pressure, headaches, reflux, vision/hearing, erection duration, sleep, and the cognitive outcome. Use a prescribed pharmacy product; counterfeit ED medication is a major sourcing risk.
Tolerance to the erectile response is not usually the central problem, but headache, congestion, blood-pressure effects, interaction risk, and psychological reliance can make continued escalation irrational; no nootropic cycling rule exists.
Bottom Line
Low-dose tadalafil can plausibly improve clarity when vascular dysfunction is part of the bottleneck, and it can just as plausibly create a 24-hour headache when it is not. Its long half-life, prescription interactions, and systemic effects make it a vascular drug with possible cognitive consequences—not a casual blood-flow supplement.
18.14 General Health and Anti-Aging as Nootropic Foundations
General health is not the boring material before the “real” nootropics. It determines whether the brain receives fuel, oxygen, hormones, sleep, and repair time at all. Treating sleep apnea, anemia, insulin resistance, thyroid disease, hypertension, depression, infection, nutrient deficiency, or medication toxicity can produce a larger cognitive change than adding an exotic mitochondrial compound.
Anti-aging matters in the same way. Aging can reduce vascular flexibility, mitochondrial quality control, muscle mass, cardiorespiratory fitness, sleep quality, and glucose regulation. Preserving exercise capacity, hearing, vision, muscle, metabolic control, and social function protects the environment in which cognition operates. The legitimate nootropic claim is therefore modest but powerful: keeping the organism healthy preserves more cognitive capacity than attempting to pharmacologically decorate a neglected organism.
18.15 How to Diagnose a Metabolic Bottleneck
1. Define the failure: sleepiness, rapid mental fatigue, slow processing, exercise intolerance, post-meal crash, memory failure, or loss of function.
2. Check the foundations: sleep quantity and apnea risk, diet adequacy, hydration, activity, infection, mood, medication, alcohol, and substance use.
3. Use medical assessment where indicated: blood count, iron and B12 status, thyroid, glucose control, kidney and liver function, blood pressure, oxygenation, and cardiovascular risk.
4. Name the proposed bottleneck before choosing the intervention.
5. Measure the bottleneck and a repeatable cognitive or functional outcome.
6. Change one variable, preserve the rest of the routine, and verify return toward baseline after discontinuation.
18.16 Metabolic Safety Standards
- A biomarker is not a benefit.
- A mechanism in cells is not a dose for humans.
- A mouse endurance result is not human cognition.
- A peptide vendor is not a pharmaceutical manufacturer.
- “Mitochondrial” does not mean safe, and “antioxidant” does not mean more is better.
- Never copy animal milligrams per kilogram directly.
- Never inject nonsterile, unverified, or research-grade material.
- Do not stack several glucose-, blood-pressure-, redox-, AMPK-, or serotonergic-active compounds without professional review.
- Treat chest pain, fainting, severe weakness, confusion, rapid breathing, jaundice, serious palpitations, and neurologic deficits as medical signals—not adaptation.
Chapter 19 — Neurotrophic and Neuroplasticity-Enhancing Compounds
Neuroplasticity is the nervous system changing itself in response to repeated experience. Neurotrophic signaling helps neurons survive, maintain branches and synapses, and become capable of that change. These words sound automatically beneficial because “growth,” “repair,” and “regeneration” imply improvement. They do not tell us whether the correct circuit changed or whether the result improved human performance.
Picture the brain as a city rebuilding roads while traffic continues. Neurotrophic factors authorize maintenance and construction; neuronal activity identifies the routes being used; metabolic health supplies electricity and materials; sleep consolidates the work. A compound may increase the construction budget, but it does not design the city. Practicing a useful skill under accurate feedback can stabilize useful wiring. Rehearsing panic, compulsions, distraction, or a bad technique can stabilize those instead.
19.1 Plasticity, Neurogenesis, Synaptogenesis, and Neuroprotection
- Neuroplasticity is the broad ability of neural circuits to change function or structure.
- Synaptic plasticity changes the strength of an existing connection.
- Synaptogenesis forms new synapses, which still must join the correct circuit.
- Neuritogenesis grows axons or dendrites.
- Neurogenesis produces and integrates new neurons; its extent and functional importance in adult humans remain debated.
- Neuroprotection preserves cells or function under a defined injury and is not synonymous with making a healthy person smarter.
19.2 Neurotrophins and Trk Receptors
BDNF signals mainly through TrkB, NGF through TrkA, and NT-3 preferentially through TrkC. These receptor tyrosine kinases recruit PI3K–Akt, MAPK/ERK, and PLCγ pathways that alter survival, metabolism, calcium, protein synthesis, and gene expression. p75NTR adds context-dependent pruning, survival, or death-related signaling.
A neurotrophin is not a universal “grow” command. It is a signed construction order interpreted differently according to receptor, cell type, developmental state, concentration, neuronal activity, and duration.
19.3 Major Neuroplasticity-Enhancing Classes
- Trk positive allosteric modulators amplify endogenous neurotrophin signaling.
- cAMP–CREB modulators prolong intracellular messages involved in longer-lasting memory.
- Neurogenic candidates were selected for progenitor-cell, hippocampal, or disease-model effects.
- HGF/c-Met modulators engage a powerful synaptogenic and tissue-growth pathway.
- Mitochondrial–neurotrophic bridges change metabolic stress signaling with downstream plasticity effects.
- Botanicals and biological mixtures introduce major product-composition problems.
- Regulatory peptides carry regional evidence and uncertain delivery.
- Growth factors, releasing hormones, and neurosteroids affect the whole organism rather than only the brain.
19.4 Trk-Receptor Positive Allosteric Modulators
19.4.1 ACD856 — Turning Up the Brain’s Response to Its Own Growth Signals
What it is: ACD856 is an experimental oral small molecule that makes the brain’s Trk receptors respond more strongly to naturally released neurotrophins such as BDNF and NGF. It has completed small Phase I studies in healthy adults, but it has not been shown to make healthy people smarter and is not an approved medication.
What it may feel like: This is not supposed to feel like amphetamine or caffeine. The limited controlled studies measured drug levels, safety, spinal-fluid exposure, and brain-wave changes—not a reliable “ACD856 feeling.” Scattered experimenter reports range from subtly better verbal access, motivation, or learning to tiredness, headache, mental flatness, and no effect; there is not enough independent reporting to know which experiences are actually caused by the compound.
The simplest description: BDNF is like an instruction telling an active circuit, “this connection matters; strengthen it.” ACD856 does not supply the instruction. It may turn up the receiving antenna, so the same natural signal is heard more loudly. This also explains why the result would be activity-dependent: studying, practicing, sleeping, and recovering decide what receives the strengthened signal.
How It Works
ACD856 is a positive allosteric modulator of TrkA, TrkB, and TrkC receptors. “Allosteric” means it binds somewhere other than the neurotrophin’s normal binding site and amplifies the receptor’s response when the natural ligand arrives. Downstream Trk signaling can engage ERK/MAPK, PI3K–Akt, and PLCγ pathways involved in synaptic function, neuronal survival, and plasticity.
That is biologically interesting but not the same as proven neurogenesis or intelligence enhancement. Plasticity makes change easier; it does not guarantee that the change is useful. Repeated distraction, anxiety, or bad habits are activity too.
Dose and How It Was Taken
Phase I investigators tested single oral doses from 1–150 mg and repeated daily doses from 10–90 mg for seven days in healthy volunteers. These were experimental oral solutions under clinical monitoring, not consumer recommendations.
The compound reached the blood rapidly when fasted. A high-fat meal slowed absorption and reduced the peak concentration by about 40%, while total exposure changed little. In plain language: food made the rise flatter and later, but did not meaningfully prevent the dose from being absorbed. No home mixing, sublingual, or intranasal method is validated.
Solubility and practical administration: Public water-, lipid-, and pH-solubility data are insufficient for consumer compounding. Phase I used a controlled oral solution that produced nearly complete exposure, but loose ACD856 powder cannot inherit that formulation’s dissolution, stability, or dose uniformity; food delayed the peak in the studied formulation rather than proving a universal fasting rule.
Timing and Pharmacokinetics
Evidence and Experiences
The human evidence establishes short-term tolerability, predictable exposure, central penetration, and dose-related qEEG changes. It does not yet establish better grades, working memory, general intelligence, or durable cognitive improvement. The studies were small and short, which means rare harms and long-term receptor adaptations remain unresolved.
Forum discussion is much larger than the number of credible experience reports. Some users describe a quiet effect that only becomes apparent during learning; others report fatigue, headache, muted emotion, or nothing. Product authenticity, expectancy, and stacks make these anecdotes useful for imagining possibilities but useless for calculating odds.
Safety, Interactions, and Monitoring
Short Phase I exposure produced no major safety signal, but that is not long-term reassurance. Potential concerns include headache, nausea, fatigue, sleep disruption, anxiety or activation, and psychiatric destabilization. Stop and seek assessment for mania, psychosis, suicidal deterioration, seizure, persistent confusion, severe neurologic symptoms, or allergic reaction.
Avoid unsupervised use in minors, pregnancy or breastfeeding, bipolar-spectrum or psychotic illness, seizure disorders, active cancer, serious liver or kidney disease, or complex psychiatric treatment. Combining it with stimulants, antidepressants, psychedelics, or other plasticity/growth compounds creates interactions that have not been studied.
Tolerance, dependence, withdrawal, and an evidence-based cycle are unknown. Because the half-life is about 20 hours, daily use accumulates and same-day redosing can be deceptive. A serious experiment would track sleep, mood, anxiety, resting heart rate, headaches, objective learning, delayed recall, error rate, and performance after stopping—not merely how “different” the brain feels.
Gray-market material requires identity testing, assay, impurities, residual-solvent analysis, and formulation verification. A label saying ACD856 does not prove equivalence to the clinical oral solution.
Bottom Line
ACD856 is one of the more scientifically credible experimental plasticity compounds because it has actual human CNS and PK data. What remains missing is the part readers care about most: proof that it meaningfully improves healthy cognition, a dependable subjective profile, and long-term safety. It is best understood as an unfinished drug candidate, not a ready-made learning upgrade.
What it is: ACD856 is an experimental oral small molecule that makes the brain’s Trk receptors respond more strongly to naturally released neurotrophins such as BDNF and NGF. It has completed small Phase I studies in healthy adults, but it has not been shown to make healthy people smarter and is not an approved medication.
What it may feel like: This is not supposed to feel like amphetamine or caffeine. The limited controlled studies measured drug levels, safety, spinal-fluid exposure, and brain-wave changes—not a reliable “ACD856 feeling.” Scattered experimenter reports range from subtly better verbal access, motivation, or learning to tiredness, headache, mental flatness, and no effect; there is not enough independent reporting to know which experiences are actually caused by the compound.
The simplest description: BDNF is like an instruction telling an active circuit, “this connection matters; strengthen it.” ACD856 does not supply the instruction. It may turn up the receiving antenna, so the same natural signal is heard more loudly. This also explains why the result would be activity-dependent: studying, practicing, sleeping, and recovering decide what receives the strengthened signal.
How It Works
ACD856 is a positive allosteric modulator of TrkA, TrkB, and TrkC receptors. “Allosteric” means it binds somewhere other than the neurotrophin’s normal binding site and amplifies the receptor’s response when the natural ligand arrives. Downstream Trk signaling can engage ERK/MAPK, PI3K–Akt, and PLCγ pathways involved in synaptic function, neuronal survival, and plasticity.
That is biologically interesting but not the same as proven neurogenesis or intelligence enhancement. Plasticity makes change easier; it does not guarantee that the change is useful. Repeated distraction, anxiety, or bad habits are activity too.
Dose and How It Was Taken
Phase I investigators tested single oral doses from 1–150 mg and repeated daily doses from 10–90 mg for seven days in healthy volunteers. These were experimental oral solutions under clinical monitoring, not consumer recommendations.
The compound reached the blood rapidly when fasted. A high-fat meal slowed absorption and reduced the peak concentration by about 40%, while total exposure changed little. In plain language: food made the rise flatter and later, but did not meaningfully prevent the dose from being absorbed. No home mixing, sublingual, or intranasal method is validated.
Solubility and practical administration: Public water-, lipid-, and pH-solubility data are insufficient for consumer compounding. Phase I used a controlled oral solution that produced nearly complete exposure, but loose ACD856 powder cannot inherit that formulation’s dissolution, stability, or dose uniformity; food delayed the peak in the studied formulation rather than proving a universal fasting rule.
Timing and Pharmacokinetics
- Subjective onset: Not established; anecdotes are too sparse and inconsistent.
- Pharmacologic onset: Systemic exposure begins rapidly after the oral solution.
- Tmax: About 30–60 minutes fasted; later with a high-fat meal.
- Absorption/bioavailability: Oral bioavailability was estimated to be nearly complete in the Phase I formulation.
- Half-life: Approximately 20 hours.
- Full practical effect: Unknown. A plasma peak is not the moment when learning or structural adaptation would be complete.
- Subjective duration: Unknown; sparse anecdotes cannot distinguish a same-day feeling from downstream learning effects.
- Accumulation/steady state: After daily dosing, Cmax accumulated about 1.6-fold and total exposure about 1.9-fold; steady state was reached before Day 6.
- Near-complete elimination: Roughly 4–5 days for most parent drug by the five-half-life convention, although downstream changes could last longer.
- Metabolism/elimination: Unchanged drug was not detected in urine, implying metabolism precedes excretion; the complete public human mass-balance pathway remains incomplete.
Evidence and Experiences
The human evidence establishes short-term tolerability, predictable exposure, central penetration, and dose-related qEEG changes. It does not yet establish better grades, working memory, general intelligence, or durable cognitive improvement. The studies were small and short, which means rare harms and long-term receptor adaptations remain unresolved.
Forum discussion is much larger than the number of credible experience reports. Some users describe a quiet effect that only becomes apparent during learning; others report fatigue, headache, muted emotion, or nothing. Product authenticity, expectancy, and stacks make these anecdotes useful for imagining possibilities but useless for calculating odds.
Safety, Interactions, and Monitoring
Short Phase I exposure produced no major safety signal, but that is not long-term reassurance. Potential concerns include headache, nausea, fatigue, sleep disruption, anxiety or activation, and psychiatric destabilization. Stop and seek assessment for mania, psychosis, suicidal deterioration, seizure, persistent confusion, severe neurologic symptoms, or allergic reaction.
Avoid unsupervised use in minors, pregnancy or breastfeeding, bipolar-spectrum or psychotic illness, seizure disorders, active cancer, serious liver or kidney disease, or complex psychiatric treatment. Combining it with stimulants, antidepressants, psychedelics, or other plasticity/growth compounds creates interactions that have not been studied.
Tolerance, dependence, withdrawal, and an evidence-based cycle are unknown. Because the half-life is about 20 hours, daily use accumulates and same-day redosing can be deceptive. A serious experiment would track sleep, mood, anxiety, resting heart rate, headaches, objective learning, delayed recall, error rate, and performance after stopping—not merely how “different” the brain feels.
Gray-market material requires identity testing, assay, impurities, residual-solvent analysis, and formulation verification. A label saying ACD856 does not prove equivalence to the clinical oral solution.
Bottom Line
ACD856 is one of the more scientifically credible experimental plasticity compounds because it has actual human CNS and PK data. What remains missing is the part readers care about most: proof that it meaningfully improves healthy cognition, a dependable subjective profile, and long-term safety. It is best understood as an unfinished drug candidate, not a ready-made learning upgrade.
19.5 cAMP–CREB Plasticity Signaling
19.5.1 BPN14770 / Zatolmilast — Keeping the Memory Signal Alive Longer
What it is: Zatolmilast, formerly BPN14770, is an investigational oral PDE4D inhibitor being developed mainly for neurodevelopmental disorders such as fragile X syndrome. It is designed to strengthen cAMP–CREB signaling with less nausea than older, broad PDE4 inhibitors.
What it may feel like: The expected profile is not raw stimulation. If it helps, the useful sensation would be that language comes together more easily, a lesson “sticks” after fewer passes, or thoughts remain organized under cognitive load. Limited online reports mention verbal fluency, easier recall, brighter mood, headache, nausea, insomnia, irritability, or no obvious acute effect, but authentic-product reports are extremely scarce.
The simplest description: When a neuron is active, cAMP helps carry the message from the cell surface toward the machinery that consolidates learning. PDE4D is one of the enzymes that erases that message. Zatolmilast partially slows the eraser, so an activity-generated signal can remain on the page longer.
How It Works
Zatolmilast is a negative allosteric modulator of long-form PDE4D enzymes. PDE4D normally breaks down cAMP; inhibiting it can prolong cAMP–PKA–CREB signaling involved in memory formation and synaptic plasticity. Its allosteric, subtype-preferring design is meant to avoid the severe nausea and vomiting that limited nonselective PDE4 inhibitors, although it does not eliminate those risks.
The activity-dependent point matters. The compound does not insert information into the brain. It may amplify biochemical signals generated while the reader is actively learning, practicing recall, and sleeping afterward.
Dose and How It Was Taken
Clinical programs have used manufactured oral tablets, commonly 10 or 20 mg twice daily in adult fragile-X studies. A single 50 mg oral dose has also been used in a human PET study to demonstrate central target engagement. These are study exposures in screened participants, not a healthy-user recommendation.
Practical water/lipid solubility, pH behavior, and food effects are not published clearly enough to justify dissolving raw powder or inventing a fasted rule. Use of a trial tablet establishes oral activity; it does not validate a gray-market powder, capsule, or sublingual method.
Timing and Pharmacokinetics
Randomized trials in fragile X syndrome provide a real clinical signal, particularly on selected cognitive and functional measures, but these participants are not healthy students. Effect sizes, endpoint selection, replication, and ongoing development still matter. Animal studies support memory effects and central cAMP engagement; they do not establish general cognitive enhancement in healthy adults.
Reddit and research-community discussion repeatedly describes it as a possible “verbal cognition” compound, but most posts explain the mechanism rather than document authenticated first-person use. Treat reports of easier word retrieval or unusually clean memory as hypotheses, not incidence data. Community discussion and mechanistic overview
Safety, Interactions, and Monitoring
PDE4 inhibition can cause nausea, diarrhea, abdominal discomfort, headache, insomnia, dizziness, appetite loss, anxiety, and mood change. Selectivity may improve tolerability; it does not make the compound side-effect-free. Stop for persistent vomiting or diarrhea, dehydration, severe agitation, mania, suicidal change, seizure, fainting, allergic reaction, or neurologic deterioration.
Avoid unsupervised use in minors, pregnancy or breastfeeding, serious psychiatric illness, seizure disorders, underweight or eating-disorder states, and significant liver or kidney disease. Combining it with other PDE inhibitors, strong enzyme modifiers, stimulants, antidepressants, or multiple plasticity agents is not clinically characterized.
Tolerance, dependence, and cycling have not been established. Monitor gastrointestinal symptoms, weight, appetite, sleep, mood, resting heart rate, and—most importantly—objective verbal learning and delayed recall. If confidence rises while errors do not fall, the experience is not evidence of cognitive enhancement.
Research-market sourcing is a major bottleneck. Identity, potency, impurities, residual solvents, and tablet equivalence need independent verification.
Bottom Line
Zatolmilast has a coherent memory-signaling mechanism and more human evidence than most gray-market “plasticity” compounds. Its best data come from impaired populations, while healthy-person PK transparency and genuine experience reports remain thin. The honest promise is “interesting clinical-stage PDE4D drug,” not “proven verbal-IQ enhancer.”
What it is: Zatolmilast, formerly BPN14770, is an investigational oral PDE4D inhibitor being developed mainly for neurodevelopmental disorders such as fragile X syndrome. It is designed to strengthen cAMP–CREB signaling with less nausea than older, broad PDE4 inhibitors.
What it may feel like: The expected profile is not raw stimulation. If it helps, the useful sensation would be that language comes together more easily, a lesson “sticks” after fewer passes, or thoughts remain organized under cognitive load. Limited online reports mention verbal fluency, easier recall, brighter mood, headache, nausea, insomnia, irritability, or no obvious acute effect, but authentic-product reports are extremely scarce.
The simplest description: When a neuron is active, cAMP helps carry the message from the cell surface toward the machinery that consolidates learning. PDE4D is one of the enzymes that erases that message. Zatolmilast partially slows the eraser, so an activity-generated signal can remain on the page longer.
How It Works
Zatolmilast is a negative allosteric modulator of long-form PDE4D enzymes. PDE4D normally breaks down cAMP; inhibiting it can prolong cAMP–PKA–CREB signaling involved in memory formation and synaptic plasticity. Its allosteric, subtype-preferring design is meant to avoid the severe nausea and vomiting that limited nonselective PDE4 inhibitors, although it does not eliminate those risks.
The activity-dependent point matters. The compound does not insert information into the brain. It may amplify biochemical signals generated while the reader is actively learning, practicing recall, and sleeping afterward.
Dose and How It Was Taken
Clinical programs have used manufactured oral tablets, commonly 10 or 20 mg twice daily in adult fragile-X studies. A single 50 mg oral dose has also been used in a human PET study to demonstrate central target engagement. These are study exposures in screened participants, not a healthy-user recommendation.
Practical water/lipid solubility, pH behavior, and food effects are not published clearly enough to justify dissolving raw powder or inventing a fasted rule. Use of a trial tablet establishes oral activity; it does not validate a gray-market powder, capsule, or sublingual method.
Timing and Pharmacokinetics
- Subjective onset: Unknown; anecdotes range from same-day verbal effects to gradual changes or no effect.
- Pharmacologic onset: Begins after oral absorption.
- Tmax: A dependable formulation-specific human value is not adequately public; preclinical work suggests a slower oral rise rather than an immediate spike.
- Half-life: Public secondary summaries place it around 10–12 hours, consistent with twice-daily trials, but a full primary human PK table is not readily available.
- Absorption/bioavailability: Oral systemic and brain exposure are demonstrated; a dependable public absolute percentage is not established here.
- Full practical effect: Cognitive trial outcomes were measured over weeks, not at Tmax.
- Subjective duration: A reproducible acute window is not established; trial regimens used repeated dosing and anecdotes vary from same-day change to none.
- Accumulation/steady state: Expected with twice-daily use, but a precise healthy-person accumulation ratio and time to steady state are not adequately published.
- Near-complete elimination: Probably several days after the last dose, but no evidence-based consumer washout should be inferred from the approximate half-life.
- Metabolism/elimination: Complete public human mass-balance details remain limited.
Randomized trials in fragile X syndrome provide a real clinical signal, particularly on selected cognitive and functional measures, but these participants are not healthy students. Effect sizes, endpoint selection, replication, and ongoing development still matter. Animal studies support memory effects and central cAMP engagement; they do not establish general cognitive enhancement in healthy adults.
Reddit and research-community discussion repeatedly describes it as a possible “verbal cognition” compound, but most posts explain the mechanism rather than document authenticated first-person use. Treat reports of easier word retrieval or unusually clean memory as hypotheses, not incidence data. Community discussion and mechanistic overview
Safety, Interactions, and Monitoring
PDE4 inhibition can cause nausea, diarrhea, abdominal discomfort, headache, insomnia, dizziness, appetite loss, anxiety, and mood change. Selectivity may improve tolerability; it does not make the compound side-effect-free. Stop for persistent vomiting or diarrhea, dehydration, severe agitation, mania, suicidal change, seizure, fainting, allergic reaction, or neurologic deterioration.
Avoid unsupervised use in minors, pregnancy or breastfeeding, serious psychiatric illness, seizure disorders, underweight or eating-disorder states, and significant liver or kidney disease. Combining it with other PDE inhibitors, strong enzyme modifiers, stimulants, antidepressants, or multiple plasticity agents is not clinically characterized.
Tolerance, dependence, and cycling have not been established. Monitor gastrointestinal symptoms, weight, appetite, sleep, mood, resting heart rate, and—most importantly—objective verbal learning and delayed recall. If confidence rises while errors do not fall, the experience is not evidence of cognitive enhancement.
Research-market sourcing is a major bottleneck. Identity, potency, impurities, residual solvents, and tablet equivalence need independent verification.
Bottom Line
Zatolmilast has a coherent memory-signaling mechanism and more human evidence than most gray-market “plasticity” compounds. Its best data come from impaired populations, while healthy-person PK transparency and genuine experience reports remain thin. The honest promise is “interesting clinical-stage PDE4D drug,” not “proven verbal-IQ enhancer.”
19.6 Neurogenic Research Compounds
19.6.1 NSI-189 Phosphate — A Slow, Unpredictable Neurogenic Antidepressant Candidate
What it is: NSI-189 is an investigational oral small molecule discovered by screening human hippocampal progenitor cells. It was developed for depression and studied primarily as the phosphate salt; its direct molecular target remains unknown.
What it may feel like: This is one of the most psychologically variable compounds in the chapter. Positive reports describe colors and music becoming richer, curiosity returning, thoughts turning into action more easily, better verbal access, and memory improvement that becomes apparent over days. Negative reports describe forehead pressure, tingling, fatigue, emotional over-intensity, anxiety, insomnia, visual changes, intrusive thoughts, or a prolonged manic/psychotic state; many feel nothing.
The simplest description: Rather than pushing dopamine or blocking sleep pressure, NSI-189 appears to change the environment in which hippocampal cells grow and adapt. If a stimulant is like pressing the accelerator, NSI-189 is closer to altering the road and the vehicle over time—which is slower, harder to predict, and potentially harder to reverse.
How It Works
NSI-189 increased neurogenesis-related measures in cell and animal work, but the direct human target is still unresolved. Hypotheses involve hippocampal progenitor growth, synaptic remodeling, and changes in neurotrophic or vascular-growth signaling. No scan or blood test in a gray-market user proves that new functional neurons were created.
The “plasticity” framing cuts both ways. A more changeable brain is not automatically a calmer or smarter brain, especially during sleep deprivation, high anxiety, trauma, or unstable mood.
Dose and How It Was Taken
The Phase Ib study administered 40 mg of NSI-189 phosphate once, twice, or three times daily for 28 days to adults with major depression. A later Phase II study tested 40 or 80 mg per day for 12 weeks. These clinical doses should not be copied into healthy self-experimentation, and phosphate-salt milligrams cannot be swapped directly with freebase milligrams.
The phosphate salt is more water-compatible than the freebase, but that does not validate sublingual use or prove that fasting is better. Clinical evidence belongs to the manufactured oral formulation. Forum claims that sublingual administration multiplies exposure are not supported by a dependable human comparison and create a redosing hazard.
Solubility and practical administration: The phosphate salt is formulated to be more aqueous-compatible than an unspecified free base, but dependable public pH-solubility and dissolution data remain limited. Clinical oral capsules—not homemade liquids—anchor the human PK, and phosphate/freebase milligrams or routes cannot be interchanged by assumption.
Timing and Pharmacokinetics
Evidence and Experiences
The Phase Ib trial was tiny. In a larger Phase II depression trial, NSI-189 did not beat placebo on the prespecified clinician-rated primary depression endpoint; selected self-rated mood and functional measures produced signals at 40 mg. That is inconclusive antidepressant evidence in depressed adults, not proof of hippocampal enlargement or healthy cognitive enhancement.
The anecdotal record is unusually vivid and unusually polarized. Some users report a delayed return of emotion, motivation, technical interest, or memory; others report severe anxiety, visual disturbance, sleep loss, or persistent psychiatric change. Stacks, unverified products, self-selection, and expectancy prevent incidence estimates. Mixed experience poll · Detailed experience discussion · Persistent psychiatric adverse report
Safety, Interactions, and Monitoring
Reported trial and community adverse effects include headache, dizziness, dry mouth, nausea, fatigue, restlessness, insomnia or poor sleep, vivid dreams, palpitations, tingling, rash, anxiety, and emotional instability. Stop and obtain urgent assessment for mania, psychosis, suicidality, persistent visual change, seizure, severe headache with neurologic symptoms, or confusion that continues after stopping.
This is especially unsuitable for unsupervised use in minors, pregnancy or breastfeeding, bipolar-spectrum or psychotic illness, seizure disorders, active cancer, serious organ disease, or alongside complex psychiatric medication. Combining it with stimulants, antidepressants, psychedelics, or other neurogenic/plasticity compounds makes attribution and risk much worse.
No evidence-based cycle exists, and human tolerance or withdrawal has not been adequately characterized. Its near-one-day half-life means repeated use accumulates for several days, and downstream psychological changes may not disappear when plasma levels do. Track sleep, mood range, anxiety, impulsivity, visual symptoms, resting heart rate, objective memory, delayed recall, and function after discontinuation. Have another person watch for behavior changes the user may not recognize.
Product form is crucial: phosphate versus freebase, assay, residual solvents, degradation, and identity must be verified independently.
Bottom Line
NSI-189 is not a conventional stimulant and not a proven brain-growth upgrade. It is a failed-or-inconclusive antidepressant candidate with real human PK, intriguing cellular origins, and a polarized anecdotal record that includes serious psychiatric warnings. The uncertainty is part of the profile, not a footnote.
What it is: NSI-189 is an investigational oral small molecule discovered by screening human hippocampal progenitor cells. It was developed for depression and studied primarily as the phosphate salt; its direct molecular target remains unknown.
What it may feel like: This is one of the most psychologically variable compounds in the chapter. Positive reports describe colors and music becoming richer, curiosity returning, thoughts turning into action more easily, better verbal access, and memory improvement that becomes apparent over days. Negative reports describe forehead pressure, tingling, fatigue, emotional over-intensity, anxiety, insomnia, visual changes, intrusive thoughts, or a prolonged manic/psychotic state; many feel nothing.
The simplest description: Rather than pushing dopamine or blocking sleep pressure, NSI-189 appears to change the environment in which hippocampal cells grow and adapt. If a stimulant is like pressing the accelerator, NSI-189 is closer to altering the road and the vehicle over time—which is slower, harder to predict, and potentially harder to reverse.
How It Works
NSI-189 increased neurogenesis-related measures in cell and animal work, but the direct human target is still unresolved. Hypotheses involve hippocampal progenitor growth, synaptic remodeling, and changes in neurotrophic or vascular-growth signaling. No scan or blood test in a gray-market user proves that new functional neurons were created.
The “plasticity” framing cuts both ways. A more changeable brain is not automatically a calmer or smarter brain, especially during sleep deprivation, high anxiety, trauma, or unstable mood.
Dose and How It Was Taken
The Phase Ib study administered 40 mg of NSI-189 phosphate once, twice, or three times daily for 28 days to adults with major depression. A later Phase II study tested 40 or 80 mg per day for 12 weeks. These clinical doses should not be copied into healthy self-experimentation, and phosphate-salt milligrams cannot be swapped directly with freebase milligrams.
The phosphate salt is more water-compatible than the freebase, but that does not validate sublingual use or prove that fasting is better. Clinical evidence belongs to the manufactured oral formulation. Forum claims that sublingual administration multiplies exposure are not supported by a dependable human comparison and create a redosing hazard.
Solubility and practical administration: The phosphate salt is formulated to be more aqueous-compatible than an unspecified free base, but dependable public pH-solubility and dissolution data remain limited. Clinical oral capsules—not homemade liquids—anchor the human PK, and phosphate/freebase milligrams or routes cannot be interchanged by assumption.
Timing and Pharmacokinetics
- Subjective onset: Same day for some reports, several days or weeks for others; many report no acute cue.
- Pharmacologic onset: Oral absorption occurs after the dose, but subjective change may lag behind plasma exposure.
- Tmax: A healthy-volunteer abstract reported a mean near 0.8 hour after a single oral phosphate dose; formulation details and variability limit consumer translation.
- Half-life: 17.4–20.5 hours in the multiple-dose depression study.
- Absorption/bioavailability: Oral absorption is demonstrated, but absolute bioavailability is not adequately public for consumer translation.
- Full practical effect: Unknown; mood and cognition were assessed over weeks. The first noticeable sensation is not evidence that remodeling is complete.
- Subjective duration: Reports range from hours of activation or fog to no acute window; claimed mood changes may persist across repeated use.
- Accumulation/steady state: Yes. Steady state was reached in roughly 96–120 hours.
- Near-complete elimination: Approximately 4–5 days for most parent compound by the five-half-life convention.
- Metabolism/elimination: Detailed human metabolic pathways and excretion fractions are not adequately public for a consumer instruction.
Evidence and Experiences
The Phase Ib trial was tiny. In a larger Phase II depression trial, NSI-189 did not beat placebo on the prespecified clinician-rated primary depression endpoint; selected self-rated mood and functional measures produced signals at 40 mg. That is inconclusive antidepressant evidence in depressed adults, not proof of hippocampal enlargement or healthy cognitive enhancement.
The anecdotal record is unusually vivid and unusually polarized. Some users report a delayed return of emotion, motivation, technical interest, or memory; others report severe anxiety, visual disturbance, sleep loss, or persistent psychiatric change. Stacks, unverified products, self-selection, and expectancy prevent incidence estimates. Mixed experience poll · Detailed experience discussion · Persistent psychiatric adverse report
Safety, Interactions, and Monitoring
Reported trial and community adverse effects include headache, dizziness, dry mouth, nausea, fatigue, restlessness, insomnia or poor sleep, vivid dreams, palpitations, tingling, rash, anxiety, and emotional instability. Stop and obtain urgent assessment for mania, psychosis, suicidality, persistent visual change, seizure, severe headache with neurologic symptoms, or confusion that continues after stopping.
This is especially unsuitable for unsupervised use in minors, pregnancy or breastfeeding, bipolar-spectrum or psychotic illness, seizure disorders, active cancer, serious organ disease, or alongside complex psychiatric medication. Combining it with stimulants, antidepressants, psychedelics, or other neurogenic/plasticity compounds makes attribution and risk much worse.
No evidence-based cycle exists, and human tolerance or withdrawal has not been adequately characterized. Its near-one-day half-life means repeated use accumulates for several days, and downstream psychological changes may not disappear when plasma levels do. Track sleep, mood range, anxiety, impulsivity, visual symptoms, resting heart rate, objective memory, delayed recall, and function after discontinuation. Have another person watch for behavior changes the user may not recognize.
Product form is crucial: phosphate versus freebase, assay, residual solvents, degradation, and identity must be verified independently.
Bottom Line
NSI-189 is not a conventional stimulant and not a proven brain-growth upgrade. It is a failed-or-inconclusive antidepressant candidate with real human PK, intriguing cellular origins, and a polarized anecdotal record that includes serious psychiatric warnings. The uncertainty is part of the profile, not a footnote.
19.6.2 P021 / P-21 — A Rodent Neurogenesis Peptide With No Human Dossier
What it is: P021 is an adamantane-modified peptide derived from a small active region of ciliary neurotrophic factor. It has produced neurogenic and memory-related findings in animal models, but it has no validated human trial, human dose, or human pharmacokinetic profile.
What it may feel like: Nobody can responsibly describe a reproducible P021 state. Sparse vendor-adjacent and forum reports mention clearer thinking, improved mood, head pressure, fatigue, or nothing, but product identity and expectation cannot be separated from the claimed effect. If a profile gives a precise onset or a confident “clean neurogenesis” sensation, it is inventing certainty that does not exist.
The simplest description: CNTF is one of the signals involved in neuronal survival and development. P021 is an engineered fragment intended to borrow part of that biological message while surviving longer than an ordinary tiny peptide. So far, the convincing story ends in laboratory animals.
How It Works
Preclinical papers propose that P021 alters leukemia-inhibitory-factor signaling and increases BDNF-related support, influencing progenitor-cell survival, synaptic proteins, and memory. Rodent work has included aging and models of Alzheimer-like pathology or neurodevelopmental disease.
This does not mean it grows a useful human hippocampus. A mouse disease model, a peptide mixed into chow, and an online nasal vial are three different products and three different experiments.
Dose and How It Was Taken
There is no validated human dose. Animal studies have used laboratory preparations delivered through chow or other controlled routes. Converting animal milligrams per kilogram into a human self-experiment would ignore species metabolism, route, formulation, brain exposure, purity, and toxicology.
Practical human solubility, pH stability, oral bioavailability, intranasal absorption, and food effects are unknown. Peptides can dissolve in water yet degrade before reaching the brain; “water-soluble” is not the same as orally bioavailable. No consumer administration recommendation is defensible.
Timing and Pharmacokinetics
Evidence is limited to cells and animals, much of it from a narrow research lineage. There are no Phase I safety data, controlled human cognitive findings, or long-term human follow-up. At least one disease-model replication attempt did not reproduce a broad benefit, which makes independent replication especially important.
Reddit and peptide forums contain far more questions and dosing claims than authenticated, well-documented experience logs. This scarcity should remain visible rather than being padded with vendor testimonials. Anecdotes cannot establish whether a vial contained P021, reached the brain, or caused the reported change.
Safety, Interactions, and Monitoring
Human adverse-effect incidence is unknown. Plausible concerns include headache, sleep or mood disruption, allergic reaction, immune effects, contamination, and unwanted growth or plasticity signaling. Intranasal or injected gray-market products add sterility, endotoxin, dosing, and tissue-injury risks.
Stop and seek care for seizure, severe or persistent headache, neurologic change, mania, psychosis, suicidal deterioration, fever, facial swelling, breathing difficulty, or signs of infection. Unsupervised exposure is inappropriate in minors, pregnancy or breastfeeding, cancer, immune disease, seizure disorders, unstable psychiatric illness, or serious organ disease.
No tolerance, dependence, cycling, or washout schedule has been established. Monitoring cannot rescue an unidentified product, but a formal study would need product assay, neurologic and psychiatric assessment, sleep, cognition, labs, and long follow-up.
For sourcing, require exact sequence identity, purity by more than one method, counterion and water content, degradation testing, and sterility/endotoxin validation for the intended route. A chromatogram supplied by the seller is not independent verification.
Bottom Line
P021 is an interesting preclinical hypothesis, not a practical nootropic. The most useful facts for the reader are the missing ones: no human dose, no human Tmax or half-life, no validated route, no reliable phenomenology, and no established safety margin.
What it is: P021 is an adamantane-modified peptide derived from a small active region of ciliary neurotrophic factor. It has produced neurogenic and memory-related findings in animal models, but it has no validated human trial, human dose, or human pharmacokinetic profile.
What it may feel like: Nobody can responsibly describe a reproducible P021 state. Sparse vendor-adjacent and forum reports mention clearer thinking, improved mood, head pressure, fatigue, or nothing, but product identity and expectation cannot be separated from the claimed effect. If a profile gives a precise onset or a confident “clean neurogenesis” sensation, it is inventing certainty that does not exist.
The simplest description: CNTF is one of the signals involved in neuronal survival and development. P021 is an engineered fragment intended to borrow part of that biological message while surviving longer than an ordinary tiny peptide. So far, the convincing story ends in laboratory animals.
How It Works
Preclinical papers propose that P021 alters leukemia-inhibitory-factor signaling and increases BDNF-related support, influencing progenitor-cell survival, synaptic proteins, and memory. Rodent work has included aging and models of Alzheimer-like pathology or neurodevelopmental disease.
This does not mean it grows a useful human hippocampus. A mouse disease model, a peptide mixed into chow, and an online nasal vial are three different products and three different experiments.
Dose and How It Was Taken
There is no validated human dose. Animal studies have used laboratory preparations delivered through chow or other controlled routes. Converting animal milligrams per kilogram into a human self-experiment would ignore species metabolism, route, formulation, brain exposure, purity, and toxicology.
Practical human solubility, pH stability, oral bioavailability, intranasal absorption, and food effects are unknown. Peptides can dissolve in water yet degrade before reaching the brain; “water-soluble” is not the same as orally bioavailable. No consumer administration recommendation is defensible.
Timing and Pharmacokinetics
- Subjective onset: Unknown in humans.
- Pharmacologic onset: Unknown for any consumer route.
- Tmax: Unknown in humans.
- Half-life: Unknown in humans; adamantane modification does not supply a clinical number.
- Absorption/bioavailability: Claimed from preclinical activity, not measured sufficiently in humans; human BBB penetration is unknown.
- Full practical effect: Unknown; rodent structural outcomes developed over repeated exposure.
- Subjective duration: Unknown because there is no credible human phenomenology.
- Accumulation/steady state: Unknown.
- Near-complete elimination: Unknown.
- Metabolism/elimination: Expected peptide cleavage plus metabolism of the modified residue, but no human mass-balance study exists.
Evidence is limited to cells and animals, much of it from a narrow research lineage. There are no Phase I safety data, controlled human cognitive findings, or long-term human follow-up. At least one disease-model replication attempt did not reproduce a broad benefit, which makes independent replication especially important.
Reddit and peptide forums contain far more questions and dosing claims than authenticated, well-documented experience logs. This scarcity should remain visible rather than being padded with vendor testimonials. Anecdotes cannot establish whether a vial contained P021, reached the brain, or caused the reported change.
Safety, Interactions, and Monitoring
Human adverse-effect incidence is unknown. Plausible concerns include headache, sleep or mood disruption, allergic reaction, immune effects, contamination, and unwanted growth or plasticity signaling. Intranasal or injected gray-market products add sterility, endotoxin, dosing, and tissue-injury risks.
Stop and seek care for seizure, severe or persistent headache, neurologic change, mania, psychosis, suicidal deterioration, fever, facial swelling, breathing difficulty, or signs of infection. Unsupervised exposure is inappropriate in minors, pregnancy or breastfeeding, cancer, immune disease, seizure disorders, unstable psychiatric illness, or serious organ disease.
No tolerance, dependence, cycling, or washout schedule has been established. Monitoring cannot rescue an unidentified product, but a formal study would need product assay, neurologic and psychiatric assessment, sleep, cognition, labs, and long follow-up.
For sourcing, require exact sequence identity, purity by more than one method, counterion and water content, degradation testing, and sterility/endotoxin validation for the intended route. A chromatogram supplied by the seller is not independent verification.
Bottom Line
P021 is an interesting preclinical hypothesis, not a practical nootropic. The most useful facts for the reader are the missing ones: no human dose, no human Tmax or half-life, no validated route, no reliable phenomenology, and no established safety margin.
19.7 HGF/c-Met Synaptogenic Modulation
19.7.1 Dihexa — A Powerful Synapse-Growth Hypothesis With No Human Trial
What it is: Dihexa is a modified angiotensin-IV-derived peptide-like molecule designed to reach the brain and amplify hepatocyte growth factor (HGF) signaling at the c-Met receptor. Its remarkable rodent findings made it famous online; there are no published human trials of Dihexa itself.
What it may feel like: The best-known long-term report describes an initially activating, elevated state followed by easier idea generation, much stronger procedural and spatial memory, better academic performance, and worse attention. Other users describe headaches, agitation, emotional change, fatigue, no effect, or concern that changes persist. These are isolated reports involving unverified powder, not a dependable human response profile.
The simplest description: HGF/c-Met helps cells grow, move, repair, and form connections. Dihexa is supposed to make that signal louder. In the brain, that could support synapse formation; elsewhere, the same pathway participates in tissue growth and cancer biology. The mechanism that makes it exciting is also the mechanism that makes casual use difficult to justify.
How It Works
Dihexa binds HGF and potentiates HGF-induced c-Met activation. Preclinical work connects this to synaptogenesis and recovery of learning in impaired rodents. Because it amplifies an existing growth signal, the result should depend on which circuits are active and what biological state the user is in.
The founding research story has also accumulated data-integrity and development concerns, and the related clinical prodrug fosgonimeton did not validate the large human promise. That does not prove Dihexa is inactive; it lowers confidence in extraordinary extrapolations.
Dose and How It Was Taken
No validated human dose or route exists. Forum users have swallowed capsules, used intranasal preparations, or applied solvents to skin, but none of these routes has measured human bioavailability or safety. A widely cited oral report used 10 mg twice weekly; it is an anecdote, not a protocol.
Dihexa is lipophilic and not conveniently water-soluble. That makes ordinary water dissolution unreliable, but it does not validate DMSO, oil injection, sublingual use, or intranasal delivery. Human food effects and formulation equivalence are unknown.
Timing and Pharmacokinetics
Evidence consists mainly of cells and rodents. There is no Phase I safety margin, no human receptor-occupancy study, no healthy cognition trial, and no cancer-surveillance dataset. This is a much weaker position than “experimental drug with disappointing efficacy”; the basic human exposure question has not been answered.
The most detailed Reddit report describes long-lasting improvements in routes, sequences, programming, and idea generation, accompanied by poorer attention. It is vivid and worth acknowledging, but one self-report cannot distinguish Dihexa from maturation, training, expectations, other drugs, or product error. Long-term experience report
Safety, Interactions, and Monitoring
The central unresolved concern is amplification of HGF/c-Met, a pathway involved in cell proliferation, angiogenesis, invasion, and metastasis. No study has shown that typical online use causes cancer—and no human program has ruled it out. Other possible harms include headache, agitation, insomnia, psychiatric change, neurologic symptoms, allergy, and route-specific contamination or tissue injury.
Avoid entirely in minors, pregnancy or breastfeeding, current or previous cancer, suspicious masses, strong cancer predisposition, serious liver or kidney disease, seizure disorders, or unstable psychiatric illness. Combining it with IGF-1, growth hormone, GHRH analogues, mTOR activators, or other growth/plasticity compounds further multiplies the uncertainty.
No evidence-based cycle, tolerance pattern, dependence profile, or washout exists. Stop for a new mass, unexplained weight loss, persistent lymph-node enlargement, bleeding, seizure, mania, psychosis, or serious neurologic change and obtain medical assessment.
Product verification would require identity, purity, degradation, residual solvents, and route-appropriate sterility/endotoxin testing. Monitoring cannot transform an uncharacterized human exposure into a safe one.
Bottom Line
Dihexa is the clearest example of why a spectacular mechanism is not enough. It might support synapses; it might also amplify biology the user does not want, and human dose, timing, elimination, efficacy, and long-term safety remain unknown. This is not a beginner compound or a defensible healthy-student recommendation.
What it is: Dihexa is a modified angiotensin-IV-derived peptide-like molecule designed to reach the brain and amplify hepatocyte growth factor (HGF) signaling at the c-Met receptor. Its remarkable rodent findings made it famous online; there are no published human trials of Dihexa itself.
What it may feel like: The best-known long-term report describes an initially activating, elevated state followed by easier idea generation, much stronger procedural and spatial memory, better academic performance, and worse attention. Other users describe headaches, agitation, emotional change, fatigue, no effect, or concern that changes persist. These are isolated reports involving unverified powder, not a dependable human response profile.
The simplest description: HGF/c-Met helps cells grow, move, repair, and form connections. Dihexa is supposed to make that signal louder. In the brain, that could support synapse formation; elsewhere, the same pathway participates in tissue growth and cancer biology. The mechanism that makes it exciting is also the mechanism that makes casual use difficult to justify.
How It Works
Dihexa binds HGF and potentiates HGF-induced c-Met activation. Preclinical work connects this to synaptogenesis and recovery of learning in impaired rodents. Because it amplifies an existing growth signal, the result should depend on which circuits are active and what biological state the user is in.
The founding research story has also accumulated data-integrity and development concerns, and the related clinical prodrug fosgonimeton did not validate the large human promise. That does not prove Dihexa is inactive; it lowers confidence in extraordinary extrapolations.
Dose and How It Was Taken
No validated human dose or route exists. Forum users have swallowed capsules, used intranasal preparations, or applied solvents to skin, but none of these routes has measured human bioavailability or safety. A widely cited oral report used 10 mg twice weekly; it is an anecdote, not a protocol.
Dihexa is lipophilic and not conveniently water-soluble. That makes ordinary water dissolution unreliable, but it does not validate DMSO, oil injection, sublingual use, or intranasal delivery. Human food effects and formulation equivalence are unknown.
Timing and Pharmacokinetics
- Subjective onset: Reports range from same-day mental activation to slow changes over weeks or no effect.
- Pharmacologic onset and Tmax: Unknown in humans.
- Absorption/bioavailability: Predicted and demonstrated preclinically, not measured adequately in humans.
- Half-life: Unknown in humans. Very long values quoted online come from preclinical whole-animal work and must not be presented as a human half-life.
- Full practical effect: Preclinical synaptic changes required time; there is no human timetable.
- Subjective duration: Unknown; reports range from same-day activation to gradual or persistent change, but none defines human PK.
- Accumulation/steady state: Unknown; potentially important if the long tissue persistence seen in animals translates at all.
- Near-complete elimination: Unknown in humans.
- Metabolism/elimination: Unknown in humans.
Evidence consists mainly of cells and rodents. There is no Phase I safety margin, no human receptor-occupancy study, no healthy cognition trial, and no cancer-surveillance dataset. This is a much weaker position than “experimental drug with disappointing efficacy”; the basic human exposure question has not been answered.
The most detailed Reddit report describes long-lasting improvements in routes, sequences, programming, and idea generation, accompanied by poorer attention. It is vivid and worth acknowledging, but one self-report cannot distinguish Dihexa from maturation, training, expectations, other drugs, or product error. Long-term experience report
Safety, Interactions, and Monitoring
The central unresolved concern is amplification of HGF/c-Met, a pathway involved in cell proliferation, angiogenesis, invasion, and metastasis. No study has shown that typical online use causes cancer—and no human program has ruled it out. Other possible harms include headache, agitation, insomnia, psychiatric change, neurologic symptoms, allergy, and route-specific contamination or tissue injury.
Avoid entirely in minors, pregnancy or breastfeeding, current or previous cancer, suspicious masses, strong cancer predisposition, serious liver or kidney disease, seizure disorders, or unstable psychiatric illness. Combining it with IGF-1, growth hormone, GHRH analogues, mTOR activators, or other growth/plasticity compounds further multiplies the uncertainty.
No evidence-based cycle, tolerance pattern, dependence profile, or washout exists. Stop for a new mass, unexplained weight loss, persistent lymph-node enlargement, bleeding, seizure, mania, psychosis, or serious neurologic change and obtain medical assessment.
Product verification would require identity, purity, degradation, residual solvents, and route-appropriate sterility/endotoxin testing. Monitoring cannot transform an uncharacterized human exposure into a safe one.
Bottom Line
Dihexa is the clearest example of why a spectacular mechanism is not enough. It might support synapses; it might also amplify biology the user does not want, and human dose, timing, elimination, efficacy, and long-term safety remain unknown. This is not a beginner compound or a defensible healthy-student recommendation.
19.8 Mitochondrial–Neurotrophic Candidates
19.8.1 J147 — Experimental Mitochondrial Stress Resistance With an Unfinished Human Story
What it is: J147 is a synthetic curcumin-derived research compound selected through cell-survival and aging-related screens rather than through a single classic receptor target. Preclinical work links it to mitochondrial ATP-synthase regulation, stress resistance, inflammation, and neurotrophic signaling.
What it may feel like: Reports are mixed but often describe something quieter than a stimulant: slightly higher daytime energy, less mental noise, easier initiation, improved enjoyment of music or social activity, and subtle clarity. Others describe initial sedation, disturbed sleep, mood changes, or nothing even after months. No controlled human study has established a characteristic experience.
The simplest description: J147 appears to make old or stressed cells handle energy and damage more like younger cells in animal models. If caffeine makes the engine rev faster, J147 is marketed conceptually as keeping an aging engine from losing efficiency—but humans have not yet shown that the repair analogy is true.
How It Works
One reported target is the alpha-F1 subunit of mitochondrial ATP synthase, with downstream changes in calcium handling, AMPK/mTOR-related signaling, inflammation, and neurotrophic pathways. Rodent studies report benefits across memory, synaptic proteins, vascular leakage, and metabolic stress.
This is a multi-pathway preclinical story, not evidence that every pathway is beneficial at every dose. It also means a subjective serotonin-like or energizing effect cannot be confidently assigned to one mechanism.
Dose and How It Was Taken
A registered Phase I study administered single ascending oral doses to fasted healthy young men and older adults, but readily accessible public results do not provide a consumer dose, complete PK table, or efficacy conclusion. Online reports commonly discuss tens of milligrams, but those amounts are not validated recommendations.
J147 is poorly suited to plain water and is generally described as lipophilic. A clinical oral formulation taken after an overnight fast does not validate homemade oil solutions, injections, or the assumption that a fatty meal improves meaningful brain exposure. Food effect, pH behavior, and absolute oral bioavailability remain insufficiently public.
Timing and Pharmacokinetics
Evidence and Experiences
The impressive evidence is overwhelmingly preclinical. A registered early human study suggests that J147 entered clinical evaluation, but without accessible results it cannot establish safe chronic use or cognitive benefit. Healthy-adult, Alzheimer’s, and long-term safety claims therefore remain unproven.
Reddit reports include modest daytime energy and clarity, a more positive outlook after months, quieter mental noise, easier action, stronger appreciation of music, initial sedation, and poorer sleep. Many reports include bromantane, phenibut, alcohol, or other compounds, making attribution especially weak. Mixed user reports · Detailed mood-oriented report
Safety, Interactions, and Monitoring
Human adverse-effect incidence and long-term organ safety are not adequately published. Possible concerns include sedation, insomnia, headache, nausea, mood destabilization, metabolic effects, and unknown mitochondrial or growth-signaling consequences. Gray-market injection adds serious formulation, sterility, depot, and tissue-injury risks and has no validated advantage.
Avoid unsupervised use in minors, pregnancy or breastfeeding, bipolar or psychotic illness, seizure disorders, active cancer, and serious liver, kidney, or mitochondrial disease. Interactions with serotonergic drugs, stimulants, sedatives, AMPK/mTOR modifiers, and other mitochondrial compounds are not adequately mapped.
There is no validated cycle, washout, tolerance model, or dependence profile. Track sleep, mood, anxiety, resting heart rate, exercise and cognitive endurance, objective recall, and function after stopping. Stop for mania, suicidality, seizure, persistent neurologic change, jaundice, severe weakness, or allergic reaction.
Product identity, assay, impurities, residual solvents, stability, and formulation need independent testing. Cost is high relative to the amount of human information obtained.
Bottom Line
J147 is a compelling aging-biology research compound with anecdotes that range from subtle energy and emotional return to sedation or nothing. Its practical human PK, chronic safety, and cognitive efficacy remain missing, so it belongs in the “watch the research” category rather than a finished nootropic protocol.
What it is: J147 is a synthetic curcumin-derived research compound selected through cell-survival and aging-related screens rather than through a single classic receptor target. Preclinical work links it to mitochondrial ATP-synthase regulation, stress resistance, inflammation, and neurotrophic signaling.
What it may feel like: Reports are mixed but often describe something quieter than a stimulant: slightly higher daytime energy, less mental noise, easier initiation, improved enjoyment of music or social activity, and subtle clarity. Others describe initial sedation, disturbed sleep, mood changes, or nothing even after months. No controlled human study has established a characteristic experience.
The simplest description: J147 appears to make old or stressed cells handle energy and damage more like younger cells in animal models. If caffeine makes the engine rev faster, J147 is marketed conceptually as keeping an aging engine from losing efficiency—but humans have not yet shown that the repair analogy is true.
How It Works
One reported target is the alpha-F1 subunit of mitochondrial ATP synthase, with downstream changes in calcium handling, AMPK/mTOR-related signaling, inflammation, and neurotrophic pathways. Rodent studies report benefits across memory, synaptic proteins, vascular leakage, and metabolic stress.
This is a multi-pathway preclinical story, not evidence that every pathway is beneficial at every dose. It also means a subjective serotonin-like or energizing effect cannot be confidently assigned to one mechanism.
Dose and How It Was Taken
A registered Phase I study administered single ascending oral doses to fasted healthy young men and older adults, but readily accessible public results do not provide a consumer dose, complete PK table, or efficacy conclusion. Online reports commonly discuss tens of milligrams, but those amounts are not validated recommendations.
J147 is poorly suited to plain water and is generally described as lipophilic. A clinical oral formulation taken after an overnight fast does not validate homemade oil solutions, injections, or the assumption that a fatty meal improves meaningful brain exposure. Food effect, pH behavior, and absolute oral bioavailability remain insufficiently public.
Timing and Pharmacokinetics
- Subjective onset: Reports range from 30–90 minutes to several days, with many nonresponders.
- Pharmacologic onset and Tmax: Human values have not been published clearly enough for practical guidance.
- Half-life: No dependable public human value.
- Absorption/bioavailability: Human oral dosing occurred, but absolute bioavailability is not adequately public.
- Full practical effect: Animal disease modification required repeated exposure; an acute mood change is not proof of the same biology.
- Subjective duration: Unknown; sparse reports range from a few hours to gradual change or nonresponse.
- Accumulation/steady state: Unknown in humans.
- Near-complete elimination: Cannot be calculated without a dependable human half-life.
- Metabolism/elimination: Not sufficiently characterized in public human data.
Evidence and Experiences
The impressive evidence is overwhelmingly preclinical. A registered early human study suggests that J147 entered clinical evaluation, but without accessible results it cannot establish safe chronic use or cognitive benefit. Healthy-adult, Alzheimer’s, and long-term safety claims therefore remain unproven.
Reddit reports include modest daytime energy and clarity, a more positive outlook after months, quieter mental noise, easier action, stronger appreciation of music, initial sedation, and poorer sleep. Many reports include bromantane, phenibut, alcohol, or other compounds, making attribution especially weak. Mixed user reports · Detailed mood-oriented report
Safety, Interactions, and Monitoring
Human adverse-effect incidence and long-term organ safety are not adequately published. Possible concerns include sedation, insomnia, headache, nausea, mood destabilization, metabolic effects, and unknown mitochondrial or growth-signaling consequences. Gray-market injection adds serious formulation, sterility, depot, and tissue-injury risks and has no validated advantage.
Avoid unsupervised use in minors, pregnancy or breastfeeding, bipolar or psychotic illness, seizure disorders, active cancer, and serious liver, kidney, or mitochondrial disease. Interactions with serotonergic drugs, stimulants, sedatives, AMPK/mTOR modifiers, and other mitochondrial compounds are not adequately mapped.
There is no validated cycle, washout, tolerance model, or dependence profile. Track sleep, mood, anxiety, resting heart rate, exercise and cognitive endurance, objective recall, and function after stopping. Stop for mania, suicidality, seizure, persistent neurologic change, jaundice, severe weakness, or allergic reaction.
Product identity, assay, impurities, residual solvents, stability, and formulation need independent testing. Cost is high relative to the amount of human information obtained.
Bottom Line
J147 is a compelling aging-biology research compound with anecdotes that range from subtle energy and emotional return to sedation or nothing. Its practical human PK, chronic safety, and cognitive efficacy remain missing, so it belongs in the “watch the research” category rather than a finished nootropic protocol.
19.9 Botanical Neurotrophic Candidates
19.9.1 Lion’s Mane / Hericium erinaceus — A Real Mushroom With an Extract-Identity Problem
What it is: Lion’s Mane is an edible mushroom containing many compounds, including hericenones associated mainly with fruiting bodies and erinacines associated mainly with cultured mycelium. “Lion’s Mane” on two labels can therefore describe chemically different products.
What it may feel like: Most people do not get an obvious acute sensation. A responder may notice after weeks that words come more easily, mood feels steadier, or studying produces less mental fatigue. Other users report headache, vivid dreams, anxiety, emotional flattening, reduced libido, skin reactions, or no effect; persistent post-use symptoms are reported online but their cause and incidence remain unknown.
The simplest description: This is not mushroom caffeine. It is closer to supplying a complicated mixture that may influence nerve-growth, immune, and gut signaling slowly. The bottle’s species, part, cultivation, and extraction decide what mixture the reader actually receives.
How It Works
Cell and animal research suggests that selected Lion’s Mane compounds can influence NGF-related signaling, neurite growth, inflammation, oxidative stress, and the gut–brain axis. Erinacine A has especially prominent preclinical neurotrophic data, but it is not present at a dependable level in every fruiting-body powder.
Human improvements, where found, do not prove that NGF rose in the brain or new neurons formed. A culinary mushroom, hot-water extract, alcohol extract, and standardized mycelial product should not be treated as interchangeable.
Dose and How It Was Taken
Human trials have used substantially different preparations, including approximately 1 g/day, 2 g/day, and 3 g/day products, while an acute young-adult crossover study used 3 g of a 10:1 fruiting-body extract. A dose without the species, mushroom part, extract ratio, extraction solvents, and assay is incomplete information.
For a general Lion’s Mane experiment, the practical default is a verified fruiting-body dual extract made with hot water and alcohol. Hot water recovers much of the water-soluble fraction, while alcohol broadens recovery toward less water-soluble constituents such as hericenones and other secondary metabolites; this gives a broader chemical extract than mushroom tea or an unspecified powder. A liquid dropper is convenient but not inherently superior to a capsule containing the same tested dual extract. Conversely, a genuinely standardized erinacine-A mycelial extract is its own specific product—not an inferior version of fruiting body—and should be judged by its assay rather than by the word “mycelium.”
Take it orally with or without food; food may improve stomach comfort, and there is no good evidence that fasting improves brain delivery. Start at the low end of the product’s studied or tested serving rather than converting an extract ratio into a fake equivalent dose. Some users deliberately take it before bed because they report sleepiness, stronger dream recall, or unusually vivid dreams, while others report insomnia or disturbing dreams. Bedtime is therefore an individual timing experiment, not evidence that Lion’s Mane has been shown to increase REM sleep; first use should be timed when a poor night would not be costly.
Timing and Pharmacokinetics
Small randomized trials in mild cognitive impairment and selected healthy samples suggest possible cognitive or mood effects, but products and outcomes vary. In a healthy-young-adult acute trial, a single extract dose produced limited task-specific findings and no overall mood benefit. The literature is promising but too small and heterogeneous for a broad intelligence claim. Healthy-young-adult randomized trial · Systematic review
Forum reports range from subtle memory and creativity gains to anxiety, anhedonia, sexual dysfunction, or prolonged symptoms. Sleep reports are especially split: some users describe more vivid or memorable dreams and better sleep when dosing at night, whereas others describe nightmares, repeated awakenings, or insomnia. These reports deserve mention without accepting speculative mechanisms—such as “more vivid dreams proves more REM”—as established. Product variation, other supplements, illness, expectation, and nocebo effects make frequency impossible to estimate. Three-month experience report · Vivid-dream reports
Safety, Interactions, and Monitoring
Common practical concerns are stomach upset, nausea, headache, rash, itching, and mushroom allergy. Stop urgently for wheezing, facial swelling, generalized hives, or breathing difficulty. Stop and reassess for major anxiety, emotional flattening, sexual dysfunction, persistent insomnia, or neurologic symptoms.
Use caution with mushroom allergy, asthma, pregnancy or breastfeeding, autoimmune disease, bleeding disorders, anticoagulants or antiplatelets, diabetes medication, and upcoming surgery. Human interaction data remain sparse.
Classic dependence is not expected, tolerance is not adequately quantified, and no cycling rule is established. Track exact brand and lot, extract type, beta-glucan and active-compound standardization, mood, sleep, libido, allergy, and an objective memory task over several weeks.
Choose products with species authentication, fruiting-body/mycelium disclosure, both hot-water and alcohol extraction stated when buying a dual extract, beta-glucan testing rather than vague “polysaccharides,” contaminant screening, and ideally hericenone or erinacine standardization. Avoid labels that hide myceliated grain inside a large “mushroom blend” number or disclose neither the extracted material nor the assay.
Bottom Line
Lion’s Mane is accessible and biologically plausible, but the product problem is enormous and the human effect is usually subtle. For most readers, a tested fruiting-body dual extract is the cleanest general-purpose choice; a standardized erinacine mycelial extract is a different, more specific experiment. Night dosing may suit someone who becomes sleepy or enjoys the dream effect, but it should be moved earlier or stopped if sleep becomes fragmented. This remains a cautious, slow experiment—not guaranteed NGF, instant focus, or proof of brain regeneration.
What it is: Lion’s Mane is an edible mushroom containing many compounds, including hericenones associated mainly with fruiting bodies and erinacines associated mainly with cultured mycelium. “Lion’s Mane” on two labels can therefore describe chemically different products.
What it may feel like: Most people do not get an obvious acute sensation. A responder may notice after weeks that words come more easily, mood feels steadier, or studying produces less mental fatigue. Other users report headache, vivid dreams, anxiety, emotional flattening, reduced libido, skin reactions, or no effect; persistent post-use symptoms are reported online but their cause and incidence remain unknown.
The simplest description: This is not mushroom caffeine. It is closer to supplying a complicated mixture that may influence nerve-growth, immune, and gut signaling slowly. The bottle’s species, part, cultivation, and extraction decide what mixture the reader actually receives.
How It Works
Cell and animal research suggests that selected Lion’s Mane compounds can influence NGF-related signaling, neurite growth, inflammation, oxidative stress, and the gut–brain axis. Erinacine A has especially prominent preclinical neurotrophic data, but it is not present at a dependable level in every fruiting-body powder.
Human improvements, where found, do not prove that NGF rose in the brain or new neurons formed. A culinary mushroom, hot-water extract, alcohol extract, and standardized mycelial product should not be treated as interchangeable.
Dose and How It Was Taken
Human trials have used substantially different preparations, including approximately 1 g/day, 2 g/day, and 3 g/day products, while an acute young-adult crossover study used 3 g of a 10:1 fruiting-body extract. A dose without the species, mushroom part, extract ratio, extraction solvents, and assay is incomplete information.
For a general Lion’s Mane experiment, the practical default is a verified fruiting-body dual extract made with hot water and alcohol. Hot water recovers much of the water-soluble fraction, while alcohol broadens recovery toward less water-soluble constituents such as hericenones and other secondary metabolites; this gives a broader chemical extract than mushroom tea or an unspecified powder. A liquid dropper is convenient but not inherently superior to a capsule containing the same tested dual extract. Conversely, a genuinely standardized erinacine-A mycelial extract is its own specific product—not an inferior version of fruiting body—and should be judged by its assay rather than by the word “mycelium.”
Take it orally with or without food; food may improve stomach comfort, and there is no good evidence that fasting improves brain delivery. Start at the low end of the product’s studied or tested serving rather than converting an extract ratio into a fake equivalent dose. Some users deliberately take it before bed because they report sleepiness, stronger dream recall, or unusually vivid dreams, while others report insomnia or disturbing dreams. Bedtime is therefore an individual timing experiment, not evidence that Lion’s Mane has been shown to increase REM sleep; first use should be timed when a poor night would not be costly.
Timing and Pharmacokinetics
- Subjective onset: Occasionally same day, more commonly days to weeks, or never.
- Tmax: Unknown for the whole mushroom; it contains many molecules with different kinetics.
- Absorption/bioavailability: Depends on constituent, preparation, food, and gut metabolism; it is not adequately quantified as one whole-extract percentage.
- Full practical effect: Cognitive studies generally assess weeks to months, not one plasma peak.
- Subjective duration: Acute digestive, sedating, activating, dream, or headache effects may occupy hours; any claimed cognitive adaptation is judged across weeks.
- Half-life: No single value exists for a multi-compound extract.
- Accumulation/steady state: Chemical accumulation and mixture-wide steady state are not established; gradual functional change may reflect adaptation rather than rising blood levels.
- Near-complete elimination: No whole-extract five-half-life estimate or formal washout exists; if adverse effects occur, stop and follow recovery to baseline.
- Metabolism/elimination: Constituents undergo different intestinal, hepatic, microbial, and renal or biliary pathways; no single mixture-wide route is valid.
Small randomized trials in mild cognitive impairment and selected healthy samples suggest possible cognitive or mood effects, but products and outcomes vary. In a healthy-young-adult acute trial, a single extract dose produced limited task-specific findings and no overall mood benefit. The literature is promising but too small and heterogeneous for a broad intelligence claim. Healthy-young-adult randomized trial · Systematic review
Forum reports range from subtle memory and creativity gains to anxiety, anhedonia, sexual dysfunction, or prolonged symptoms. Sleep reports are especially split: some users describe more vivid or memorable dreams and better sleep when dosing at night, whereas others describe nightmares, repeated awakenings, or insomnia. These reports deserve mention without accepting speculative mechanisms—such as “more vivid dreams proves more REM”—as established. Product variation, other supplements, illness, expectation, and nocebo effects make frequency impossible to estimate. Three-month experience report · Vivid-dream reports
Safety, Interactions, and Monitoring
Common practical concerns are stomach upset, nausea, headache, rash, itching, and mushroom allergy. Stop urgently for wheezing, facial swelling, generalized hives, or breathing difficulty. Stop and reassess for major anxiety, emotional flattening, sexual dysfunction, persistent insomnia, or neurologic symptoms.
Use caution with mushroom allergy, asthma, pregnancy or breastfeeding, autoimmune disease, bleeding disorders, anticoagulants or antiplatelets, diabetes medication, and upcoming surgery. Human interaction data remain sparse.
Classic dependence is not expected, tolerance is not adequately quantified, and no cycling rule is established. Track exact brand and lot, extract type, beta-glucan and active-compound standardization, mood, sleep, libido, allergy, and an objective memory task over several weeks.
Choose products with species authentication, fruiting-body/mycelium disclosure, both hot-water and alcohol extraction stated when buying a dual extract, beta-glucan testing rather than vague “polysaccharides,” contaminant screening, and ideally hericenone or erinacine standardization. Avoid labels that hide myceliated grain inside a large “mushroom blend” number or disclose neither the extracted material nor the assay.
Bottom Line
Lion’s Mane is accessible and biologically plausible, but the product problem is enormous and the human effect is usually subtle. For most readers, a tested fruiting-body dual extract is the cleanest general-purpose choice; a standardized erinacine mycelial extract is a different, more specific experiment. Night dosing may suit someone who becomes sleepy or enjoys the dream effect, but it should be moved earlier or stopped if sleep becomes fragmented. This remains a cautious, slow experiment—not guaranteed NGF, instant focus, or proof of brain regeneration.
@Volpa #Volpamogs
Last edited:
